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1 Abstract 
Although p75 neurotrophin receptor (p75NTR) is the first neurotrophin receptor isolated, its 
precise functions in physiology and underlying signaling have remained elusive for many 
years. In this study, endoplasmic reticulum retained intrabody (ER-intrabody) technology was 
applied to knockdown p75NTR surface expression in mammalian cells. By fusing with the C-
terminal ER retention signal KDEL, ER-intrabody impedes target receptor protein from 
secretory trafficking. 
Monoclonal recombinant scFvs against p75NTR were isolated by phage display. These 
scFvs bound to p75NTR with nanomolar affinities and were used to generate p75NTR-
specific ER-intrabodies. In neuron-like cell lines PC12 and NSC19, p75NTR surface 
expression was significantly suppressed by the p75NTR-specific ER-intrabody construct 
SH325-G7-KDEL. The effect of this ER-intrabody on p75NTR surface knockdown could be 
maintained over a period of more than eight days without obviously activating unfolded 
protein response (UPR). Finally, the downregulation of p75NTR surface expression was 
determined in mouse hippocampal primary cultures using the ER-intrabody SH325-G7-KDEL. 
Sholl analysis showed that dendritic complexity of neurons was significantly increased if the 
p75NTR expressions were reduced on their surfaces by the ER-intrabody.  
In conclusion, the novel ER-intrabody SH325-G7-KDEL inhibits the surface translocation of 
p75NTR and ER-intrabody knockdown technology may become a powerful tool to investigate 
molecular mechanisms of target neuronal receptors. 
  Zusammenfassung 
2 
 
Zusammenfassung 
Obwohl der Neurotrophinrezeptor p75 (p75NTR) als einer der ersten Neurotrophinrezeptoren 
isoliert wurde, ist seine physiologische Funktion und seine Beteiligung an 
Signaltransduktionswegen bis heute noch nicht vollständig erforscht. In der vorliegenden 
Arbeit wurden intrazellulären Antikörper (intrabodies) eingesetzt, um einen phänotypischen 
knockdown des Oberflächenproteins p75NTR auf Säugerzellen zu erreichen. Bei dieser 
Technik, die auf posttranslationaler Ebene wirkt, wird die Sekretion des Zielantigens 
verhindert, indem man an einen spezifischen Antikörper ein ER-Retentionssignal anhängt. 
Dieses Retentionssignal ist für den Verbleib des Zielproteins im ER (Endoplasmatisches 
Retikulum) der Zelle verantwortlich. 
Mittels der Phage Display Technologie wurden verschiedene scFvs gegen p75NTR isoliert. 
Alle scFvs wiesen nanomolare Affinität gegenüber ihrem Antigen auf und wurden im weiteren 
Verlauf der Arbeit in ER-intrabodies umkloniert. Nach einer transienten Transfektion von 
p75NTR-positiven Zelllinien (PC12 und NSC19) mit dem intrabody SH325-G7-KDEL konnte 
mittels Durchflusszytometrie eine signifkante Herunter Regulation des p75NTR-
Oberföächenproteins gezeigt werden. Dieser Effekt konnte über einen Zeitraum von acht 
Tagen aufrechterhalten werden, ohne dabei dem unfolded protein response (UPR), einen 
Stressindikator der Zelle, zu aktivieren. Weiterhin wurde der Effekt des intrabody SH325-G7-
KDEL in murinen, primären Hippocampuszellen untersucht. Nach transienter Transfektion 
konnte mittels Sholl-Analyse gezeigt werden, dass eine reduzierte p75NTR-
Oberflächenexpression zu einer signifikant erhöhten Komplexität der Neuronen führte. 
Zusammenfassend wurde mit den in dieser Arbeit isolierten funktionellen ER-intrabodies ein 
weiteres Beispiel dafür gegeben, dass der posttranslationale Knockdown von Proteinen eine 
viel versprechende Methode ist, um die molekularen Mechanismen von 
Oberflächenproteinen zu untersuchen. 
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2 Introduction 
2.1 Recombinant antibody and phage display technology  
2.1.1 Antibodies and recombinant antibody fragments 
Antibodies (Abs), also known as immunoglobulins (Igs), are important in the immune system 
to identify and neutralize exogenous intruders including toxins, bacteria, viruses, and fungi. 
They are produced by B cells, and found in blood or other bodily fluids of vertebrates and 
compose of five isotypes: IgA, IgD, IgE, IgG, and IgM. The isotypes and functions of Igs are 
determined by the heavy chain types. The most abundant isotype in serum for the immune 
system of vertebrates is IgG, which is assembled by two identical γ heavy chains (HC) and 
two identical κ or λ light chains (LC) connected by disulfide bonds and non-covalent bonds. 
The molecular masses of HC and LC are about 50 kDa and 25 kDa, respectively. Both HC 
and LC of IgG contain variable and constant regions. The LC is composed of one variable 
(VL) and one constant (CL) domain, while the HC has one variable (VH) and three constant 
(CH1, CH2, and CH3) domains (Delves, 2006).  
 
Figure 2.1 Schematic representations of IgG and recombinant scFv. Reproduced from 
(Dübel, 2007).  
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The structure of IgG, shown in Fig. 2.1, is represented as a Y shape by one Fc (fragment, 
crystallizable) at the bottom and two identical Fabs (fragment, antigen binding) at the tip, 
linked by flexible hinge regions. Fc region is responsible for effector function of an IgG to 
ensure that an appropriate immune response after antigen binding is mediated by the 
antibody. Antigen-binding site is formed by hypervariable regions of VL and VH in Fv 
(fragment, variable). Because antigen-binding site is complementary to the structure of 
epitope, hypervariable regions are also called complementarity-determining regions (CDRs). 
The CDRs are sequences of the highest variability and embedded into less variable  
framework regions (FRs) (Kabat et al., 1979).  
According to the structure of antibodies, it is well known that the antigen determining regions 
of an antibody are separated from the effector function mediating regions. Therefore, it is 
possible to produce antibody fragment as F(ab’)2, Fab, or Fv (Kontermann and Dübel, 2001). 
Fv fragment is the smallest antigen binding fragment containing the entire antigen binding 
capacity and specificity of the corresponding antibody molecule, because it consists of VL 
and VH domains. However, Fv fragment is normally unstable since VL and VH domain are 
not connected by a disulfide bond. This problem was solved by engineering the single-chain 
Fv (scFv) fragment (Fig. 2.1). The stability of scFvs is increased by linking the VL and VH 
domains with a flexible 15-20 amino acid peptide linker. The successful production of 
recombinant antibodies in the periplasmatic space of E. coli allows the generation and 
selection of antibody fragments because the oxidizing environment is required for the 
formation of disulfide bonds (Better et al., 1988; Skerra and Pluckthun, 1988; Pluckthun, 
1990). To date, scFv has become an important tool for research, diagnostics and therapy 
and has been produced in various production systems including Gram-negative and Gram-
positive bacteria, yeast, fungi, insect cells as well as mammalian cells (Schirrmann et al., 
2008).  
 
2.1.2 Phage display technology 
Many techniques have been developed to generate monoclonal antibodies or antibody 
fragments with predefined antigen specificities including hybridoma technology (Köhler and 
Milstein, 1975), phage display (Azzazy and Highsmith, 2002), bacterial surface display 
(Fuchs et al., 1991), ribosomal display (Hanes and Pluckthun, 1997), puromycin display 
(Roberts and Szostak, 1997), and yeast surface display (Boder and Wittrup, 1997). Among 
these methods, phage display has developed into the most robust, versatile and thus 
widespread selection method in the past two decades. Phage display is not only used to 
select antibody fragments, but also to isolate other peptides and proteins with high affinity 
and specificity for almost any target. This technique can also be used to study protein-ligand 
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interactions, receptor and antibody-binding sites, and to improve or modify the affinity of 
proteins for their binding partners (Azzazy and Highsmith, 2002). 
 
Filamentous bacteriophage 
The groundbreaking work for phage display was achieved by G. P. Smith based on 
filamentous bacteriophage M13 (Smith, 1985). Bacteriophages, or simply phages, are 
viruses that infect a variety of Gram-negative bacteria, such as E. coli, which produce and 
secrete phage particles without undergoing lysis. The best characterized filamentous phages, 
M13, f1 and fd, belong to the Ff filamentous phage family and infect E. coli via their F pili. 
These particles are rods about 6.5 nm in diameter and 900 nm in length (Russel et al., 1997). 
M13 phage consists of a circular single-stranded DNA (ssDNA) that contains 11 genes. The 
entire genome is enveloped by ~2700 copies of the 50-residue major coat protein, pVIII. 
Besides the major coat protein, 3-5 copies for each minor coat protein located at the 
terminuses of M13 phage particles. At one terminus, protein pVII and pIX, are necessary for 
efficient particle assembly, while protein pVI and pIII, which response to phage stability and 
infectivity, are expressed at the other terminus (Fig. 2.2).  
 
 
Figure 2.2 Schematic structure of M13 phage. 
 
Phagemid and helperphage 
The remarkable aspect of phage display is the linkage between the phenotype and genotype 
of antibody fragments. This is achieved by fusing the gene encoding antibodies typically to 
the minor coat pIII protein gene of M13 phage. The resulting surface presentation of this 
antibody::pIII fusion protein allows the selection and affinity purification of the desired gene 
from libraries of billions of phage clones (McCafferty et al., 1990).  Only the antibody 
fragments, Fab, Fv, scFv, and more recently scFab are used for antibody phage display, due 
to the limitations of E. coli folding machinery that complete IgG molecules can hardly be 
expressed in E. coli and displayed on the surface of phage (Better et al., 1988; Skerra and 
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Pluckthun, 1988; Hust et al., 2007a). Antibody genes can be directly fused to the wild-type 
pIII gene in phage genome (McCafferty et al., 1990), or antibody::pIII fusion proteins can be 
expressed in phagemids independent from the phage genome (Hust and Dübel, 2005). 
Phagemid contains origins of replications of both M13 phage and E. coli in addition to a 
resistance marker and can be grown as plasmids (Mead and Kemper, 1988). Phagemid can 
be packaged into a complete phage with the aid of helperphage, such as M13KO7 or 
VCSM13, that complement all the phage genes not encoded on phagemid (Vieira and 
Messing, 1987). However, only 1-10% of phages display a antibody fragment by using 
M13KO7 for packing, due to the competition of antibody::pIII fusion protein with wildtype pIII 
during phage assembly (Rondot et al., 2001). In 2001, Rondot et al. induced a novel 
helperphage, namely hyperphage, resulting in a significant increase in the fraction of phages 
displaying antibody fragments. Hyperphage has a truncated pIII gene on the phage genome; 
thereby the antibody::pIII fusion protein encoded on the phagemid is the only source for 
complete phage assembly. A number of phagemids have been constructed such as pHAL14 
shown in Fig. 2.3 (Hust et al., 2007b). 
 
 
Figure 2.3 Schematic representation of pHAL14 phagemid. Lac Pr.: Lac Z promoter; RBS: 
ribosomal binding site; pelB: pelB leader from the pectate lyase gene of Erwinia caratovora; VH: 
variable heavy chain; VL: viarable light chain; gIII: gene III encoding pIII protein; colE1: colE1 
replication origin for phagemid; bla: beta-lactamase; M13 ori: replication origin for M13 phage. The 
drawing was originally designed by Dr. Michael Hust (Institute for biochemistry and biotechnology, TU 
Braunschweig). 
 
The pHAL14 vector is derived from the phagemid vector pHAL1 and expresses a scFv 
cloning cassette by cloning VH into NcoI/HindIII site and VL into MluI/NotI site. It contains a 
lac Z promoter (lac Pr.) derived from the lactose operon (Jacob and Monod, 1961) and a Yol 
linker connecting VH and VL for library cloning (Breitling et al., 1991). In order to target the 
antibody fragments to the periplasmatic space of E. coli, a pelB leader from the pectate lyase 
gene of Erwinia caratovora is ligated to the 5’ end of the antibody::pIII encoding sequence 
(Skerra and Pluckthun, 1988). The antibody expressed from the pHAL14 vector includes a 
His6 tag and a c-myc tag for detection and purification. 
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Antibody library 
The genetic diversity of an antibody library is essential for selecting specific antibodies 
efficiently. There are four types of antibody library that have been constructed. The 
amplification of variable genes of IgG secreting plasma cells from immunized donors is used 
to generate immune libraries (Clackson et al., 1991). Immune libraries are normally used to 
generate antibodies to a specific antigen such as an infectious pathogen, therefore popular in 
medical research. Compared to immune libraries, naïve, semi-synthetic and synthetic 
libraries are known as ‘single-pot’ libraries according to their capacities to isolate antibodies 
against any possible antigen. Naïve libraries are constructed from rearranged antibody genes 
from Ig secreting B-cells of non-immunized donors. Semi-synthetic libraries can be created 
from unrearranged variable genes from pre-B cells (germline cells), or from a single antibody 
framework with at least one CDR region, typically CDR3 of the heavy chain for its high 
diversity, genetically randomized. The fully synthetic libraries are derived from a human 
framework with randomly integrated CDR cassettes (Hayashi et al., 1994; Pini et al., 1998; 
de Haard et al., 1999). Up to date, single-pot antibody libraries with a theoretical diversity of 
up to 1011 independent clones have been generated and used for the selection of antibodies 
for diagnostic and therapeutic purposes (Thie et al., 2008). 
 
Panning 
The technique for selecting specific antibodies in vitro via screening and enriching the 
antibody libraries are known as panning (Parmley and Smith, 1988). A typical selection cycle 
is illustrated in Fig. 2.4. The antigen of interest is immobilized on a solid surface, for instance 
96-well polystyrole microtiter plates (Barbas et al., 1991), nitrocellulose (Hawlisch et al., 
2001), polystyrole tubes (Hust et al., 2002), or magnetic beads (Moghaddam et al., 2003). 
The microtiter plates and polystyrole tubes are most widely used. The conformational 
integrity of antigens during the immobilization is critical to obtain functionally specific 
antibodies. Some antibodies selected against an adsorbed antigen may not be able to 
recognize the native form antigen (Sanna et al., 1995). Indirect antigen immobilization using 
antigen-specific capture antibodies may avoid this problem.  
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Figure 2.4 Schematic description of the selection of antibody fragments from antibody 
libraries by phage display (panning). 
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Antibody phages are firstly incubated with immobilized antigens. Unbound antibody phages 
are then removed by thorough washing. Bound phages are subsequently eluted by changing 
the binding conditions and re-amplified by infection of E. coli. Because the binding of 
nonspecific phage limits the enrichment achieved per cycle, usually 2-6 panning rounds are 
necessary to select specifically antibody phages in practice. In the end, individual antibody 
clones can be identified by monoclonal ELISA. More details about panning can be seen in 
Kontermann and Dübel (2001). 
 
2.2 ER-intrabody knockdown technology 
2.2.1 Intracellular antibody 
Intracellular antibodies, or called intrabodies, are designed to be expressed and function 
within intracellular compartments. Due to the development of recombinant antibody 
engineering, various antibody formats have been used as intrabodies including Fabs, scFvs, 
single-chain diabodies, or even intact IgG molecules (Kontermann, 2004). Because of the 
small size, scFvs are easily expressed and assembled as functional molecules intracellularly, 
therefore the most commonly formats applied. In the past decade, more and more 
intrabodies have been isolated from phage display libraries and used in a wide range of 
applications, including HIV infection, tumor therapy, tissue transplantation, and treatments of 
neurological disorders (Kontermann, 2004; Miller and Messer, 2005; Boldicke, 2007). 
According to high specificities and high affinities to target antigens, intrabodies have been 
used as a biotechnological tool to block intermolecular interactions, and to modulate proper 
functions of defined target proteins at the posttranslational level. In order to exert their 
functions, intrabodies have to be directed to and/or retained in various subcellular locations 
including the cytosol, nucleus, endoplasmic reticulum (ER), mitochondria, peroxisome, 
plasma membrane and trans-Golgi network (TGN) through fusion to a variety of signal and/or 
retention peptides. For instance, an intrabody can be trafficked to ER by an antibody signal 
peptide and retarded by constructing an ER retention signal at carboxy-terminal (Boldicke, 
2007). In addition, farnesylation signals or nuclear localization signals (NLS) can direct 
intrabodies to plasma membrane or nucleus in mammalian cells effectively (Yoneda et al., 
1992; Kalejta et al., 1997). 
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2.2.2  ER-intrabody  
Intrabodies combined with the ER retention peptides are known as ER retained intrabodies 
or ER-intrabodies (Fig. 2.5). KDEL is one of the most common ER retention sequences. It is 
a conserved carboxy- terminal tetrapeptide (Lys-Asp-Glu-Leu) that serves as a retrieval 
signal to retain the majority of ER resident proteins within the ER.  
 
 
Figure 2.5 Schematic representation of an ER-intrabody in scFv format. VH: variable 
domain of heavy chain; VL: variable domain of light chain; Linker: a flexible 15-20 amino acid peptide 
linking VH and VL domains. 
 
The KDEL signal has been demonstrated to be recognized by a receptor that is encoded by 
the ERD2 gene, and a human homologue of ERD2 (hERD2) has been identified (Lewis and 
Pelham, 1992a). Soon afterwards, Lewis and Pelham identified another related human 
receptor with similar function of human ERD2 (Lewis and Pelham, 1992b). After induction of 
hERD2 oligomerization by KDEL, COPI-coated budding protein complexes are formed 
containing ER resident proteins and hERD2 receptors. Associated with ADP-ribosylation 
factor GTPase activating protein (ArfGAP), the protein complexes are recycled back to the 
ER. The affinity of KDEL receptors for KDEL is pH-dependent (Wilson et al., 1993).  Due to 
the pH differences, the KDEL sequence binds to the KDEL receptor with a high affinity at the 
acidic pH of the Golgi lumen and releases from the KDEL receptor after retrieval to the ER 
because the affinity is decreased by the neutral pH of the ER lumen. The proteins 
dissociated from the receptors may be degraded by the cytoplasmic proteosome according to 
ER-associated protein degradation (ERAD) (Meusser et al., 2005).  
 
2.2.3 Mechanism of ER-intrabody knockdown technology 
Combining the high specificity and affinity of intrabodies and the retention function of the 
KDEL peptide, ER-intrabodies inhibit the translocation of specific target surface molecules 
from the ER to the cell surface (Munro and Pelham, 1987; Boldicke, 2007), which results in a 
very efficient knockdown of the cell surface expressions of specific target molecules (Fig. 2.6). 
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In a mammalian cell, target surface proteins are continuously expressed and transported to 
the surface (Fig. 2.6A). After introducing the plasmid of ER-intrabody specific to the target 
(Fig. 2.6B), ER-intrabodies are expressed and bind to the target proteins within the ER to 
form the complexes consisting of ER-intrabodies and target proteins (Fig. 2.6C). Due to the 
KDEL peptide, the complexes are translocated in COPI-coated vesicles and then recycled 
between the Golgi complex and the ER (Fig 2.6C). Finally, the knockdown, or even 
phenotypic knockout of the target proteins from the cell surface is achieved (Fig. 2.6D). 
   
Figure 2.6 ER-intrabody in a target surface molecule knockdown. (A) The target proteins 
(shown in green) are expressed and transported to the cell surface. (B) The plasmids (shown in red) 
encoding ER-intrabody specific to the target proteins are introduced and expressed. (C) Due to the 
KDEL peptide, the complexes of ER-intrabodies and the target proteins are translocated in the COPI-
coated vesicles and recycled between the Golgi complex and the ER. (D) The surface expression of 
target proteins is inhibited. (Modified based upon an unpublished drawing by S. Dübel). 
 
ER-intrabodies are potentials to study specific protein functions and can also be used in 
therapeutic applications. The crosstalk between ErbB-2 and the androgen receptor was 
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verified by applying an anti-ErbB-2 ER-intrabody (Liu et al., 2005). In spite of the limitation of 
gene delivery, intraperitoneal delivery of adenovirus encoding the anti-ErbB-2 ER-intrabody 
enhanced survival and reduces tumor growth in a xenograft model of human ovarian 
carcinoma in SCID mice (Deshane et al., 1997). Furthermore, ER-intrabodies have been 
broadly used to interrupt the HIV-1 viral life cycle. It has been shown that the HIV-1 
glycoprotein gp120, its precursor gp160 and corresponding co-receptors CCR5 or CXCR4 
were targeted by ER-intrabodies, and the virus-mediated syncytial formation was 
subsequently blocked, which led to low infectivity of progeny HIV particles (Boldicke, 2007). 
ER-intrabodies have also been applied in neurodegenerative disorders, for example, to study 
the biogenesis of Alzheimer’s disease (AD) and prion diseases. It has been determined that 
the generation of Aβ and PrPsc, which play important roles in AD and prion diseases 
respectively, can be experimentally inhibited by ER-intrabodies (Paganetti et al., 2005; 
Vetrugno et al., 2005). 
 
2.3 P75 neurotrophin receptor (p75NTR) 
P75 neurotrophin receptor (p75NTR) was the first neurotrophin receptor identified; however, 
its precise physiological role has remained elusive for many years. In contrast to  the tyrosine 
kinase receptor (Trk) family,  p75NTR has a similar low affinity without selectivity for all 
neurotrophins (NT),  which have been known as the essential factors in the development and 
functioning of the nervous system (Arevalo and Wu, 2006). Four neurotrophins have been 
identified in mammals: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT-3) and neurotrophin 4 (NT-4) (Lu et al., 2005). Recent work also found 
that neurotrophins arise from precursors, known as proneurotrophins, which will bind 
p75NTR with high affinity (Lee et al., 2001). The expression of p75NTR changes during the 
life span of an organism. It is abundantly expressed throughout the central nervous system 
(CNS) on neurons and glia during development period, while its expression decreases 
remarkably in adult animals. In addition, the expression of p75NTR can be induced in the 
neurons after injury (Chao, 2003). P75NTR is also expressed in blood vessel smooth muscle 
cells as well, although its role in these cells is not yet clear (von Schack et al., 2001). 
 
2.3.1 Molecular structure of p75NTR   
P75NTR is a single-pass type I transmembrane protein that consists of an extracellular 
domain, a transmembrane domain and an intracellular domain (Fig. 2.7) (Johnson et al., 
1986). The structure of human p75NTR gene was identified as 75,000 base pairs in size, 
containing 10 exons and nine introns (Johnson et al., 1986; Santee and Owen-Schaub, 
1996). Full-length p75NTR includes four cysteine-rich domains (CRDs) in the extracellular 
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domain which are negatively charged and subsequently recognized as the defining 
characteristic of tumor necrosis factor receptor (TNFR) superfamily. The CRDs are encoded 
in exon III and the third and fourth CRDs are determined to be required for neurotrophin 
binding (Dechant and Barde, 2002). A stalk domain connecting the single transmembrane 
domain attaches to the CRDs and is involved in the sorting of p75NTR and the 
transmembrane domain is highly conserved across species. The intracellular part of p75NTR 
is composed of a juxtamembrane domain and a globular, six-helix carboxy-terminal domain, 
known as the death domain, which is associated in apoptosis signal transduction (Coulson et 
al., 2000). Unlike the other members in the TNFR family, the death domain of p75NTR 
belongs to subtype II, which is different from the subtype I death domains of other TNFR 
receptors (Bender and Thorburn, 2005).  
 
Figure 2.7 Schematic structure of p75NTR. Reproduced from Dechant and Barde (2002). 
 
2.3.2 Diverse functions of p75NTR depending on co-receptors 
P75NTR normally has to collaborate with many different protein partners to induce several 
cellular responses, since its intracellular region does not exhibit an intrinsic ligand-inducible 
enzymatic function as Trk receptors (Hempstead, 2002). Trk receptors were the first co-
receptors identified for p75NTR as the p75NTR and Trk receptors interaction will increase 
the affinity and selectivity of neurotrophin binding (Bibel et al., 1999). Besides Trk receptors, 
sortilin, LINGO-1, and NgR have been demonstrated as co-receptors of p75NTR to produce 
different biological responses (Lu et al., 2005).  
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2.3.2.1 P75NTR regulates the cell death or cell survival in the absence of Trk receptors 
P75NTR is to promote apoptotic effects in response to neurotrophins depending on the 
molecular and cellular context. Overexpression of p75NTR alone is enough to cause cell 
death (Rabizadeh et al., 1993). In the absence of Trk receptors, the apoptotic effects can be 
mediated by p75NTR via several different pathways (Fig. 2.8), which can be counteracted by 
TrkA presence (Yoon et al., 1998). 
 
 
Figure 2.8 P75NTR regulates either cell death or cell survival in response to 
neurotrophins in the absence of Trk receptors. 
 
Although the signaling pathways of p75NTR-dependent apoptotic response are less clear, it 
has been elucidated that Jun amino-terminal kinase (JNK) is involved. JNK has been 
determined to be activated by many interactors, including NT-receptor interacting factor 
(NRIF), NT-associated cell death executor (NADE), NT-receptor-interacting MAGE homolog 
(NRAGE) and TNF receptor-associated factors (TRAFs), which will work alone or in 
combination (Yeiser et al., 2004). Coexpression of NRIF and TRAF6 in p75NTR-expressing 
cells will induce activation of JNK and promote cell death (Gentry et al., 2004b). Besides JNK 
activation, NRAGE also interacts with p75NTR to promote apoptosis through activating 
caspases-3, -7, and -9 (Salehi et al., 2000). The NADE-dependent signaling pathway is 
selectively responsible to NGF binding to p75NTR, but not BDNF or NT-3/4 binding (Mukai et 
al., 2000).  
Intriguingly, NGF binding to p75NTR leads to promote survival response by activating 
transcription factor, nuclear factor kappa B (NF-κB), in rat Schwann cells, although this is not 
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completely understood (Dechant and Barde, 1997). This activation was not observed in 
Schwann cells isolated from p75NTR-deficient mice. The activation of NF-κB is selective for 
NGF and not activated by BDNF or NT-3 (Carter et al., 1996). The activation of NF-κB 
requires several proteins, including TRAF6, p62, interleukin-1 receptor-associated kinase 
(IRAK), and receptor-interacting protein-2 (RIP2) (Arevalo and Wu, 2006). Upon activation, 
NF-κB is translocated to the nucleus and traggers the expression of Hes 1/5 to modulate 
dendritic growth (Salama-Cohen et al., 2005).  
 
2.3.2.2 P75NTR acts as a pro-survival receptor in the presence of Trk receptors 
P75NTR may act as a co-receptor of the Trk receptors to enhance the survival of neurons. It 
has been identified to augment Trk signaling by stimulating the phosphorylation of Shc, a Trk 
adaptor (Epa et al., 2004). It has been proposed that p75NTR enhances the affinity and 
specificity of Trk receptors for neurotrophins. The subdomain of Trk receptor is altered by 
p75NTR interaction to expose a special site for neurotrophin binding (Zaccaro et al., 2001).  
The affinity of Trk receptor to neurotrophin can increase from 10-9 M to 10-11 M. Another 
group found the evidence that p75NTR increased the affinity of TrkA for NGF while impeding 
its binding of NT-3 (Kuruvilla et al., 2004). Recent research demonstrated that the crystal 
structure of p75NTR and NGF complex was asymmetric (He and Garcia, 2004). One 
p75NTR bound to a dimeric NGF and the conformation of the complex was unable to recruit 
another p75NTR but suggested binding to another co-receptor, such as Trk receptor, to form 
a heterodimeric complex. However, Wehrman and colleagues lately proposed that p75NTR 
and TrkA most likely communicated in the downstream signaling pathway rather than through 
direct extracellular interaction. They found that NGF dimerized TrkA and p75NTR existed on 
the cell surface as a preformed oligomer that did not dissociated by NGF (Wehrman et al., 
2007). Thereby it assumed that the Trk-mediated signaling was enhanced via p75NTR 
communicating with Trk receptors through the cytosolic and/or transmembrane domains 
(Nykjaer et al., 2005). The signaling pathways of Trk dimer-p75NTR receptor complexes 
might be inherently different from those of Trk dimers. TrkA dimers are sufficient to sustain 
neurite outgrowth, whereas the heteromeric TrkA dimer-p75NTR complex is necessary for 
complete outgrowth and for long-term survival (Lad et al., 2003). 
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Figure 2.9 P75NTR acts as a co-receptor of Trk receptors for neurotrophins to enhance 
the survival of neurons. 
 
Activated TrkA elicits the Ras-mitogen-activating protein (MAP) kinase pathway in the 
absence of p75NTR, but TrkA can stimulate the PI3-kinase-protein kinase B (Akt) cascade 
only in the presence of 75NTR (Fig. 2.9) (Nykjaer et al., 2005). It has recently been identified 
that TrkA and p75NTR promoted NGF-dependent neurite outgrowth through activating fas 
apoptosis inhibitor molecule (FAIM) (Sole et al., 2004). FAIM is recognized as an adaptor 
that can bind both TrkA and p75NTR and the neurite outgrowth is thought to invoke 
activation of both NF-κB and the Ras-MAP kinase pathway. 
 
2.3.2.3 Sortilin-p75NTR complex is essential for proneurotrophin-induced neuronal cell 
death 
P75NTR alone can activate pro-apoptotic effects via binding mature neurotrophins; however, 
the neurotrophin-induced p75NTR-dependent apoptosis is not efficient. High non-
physiological concentrations of mature neurotrophins are often required to induce even 
modest levels of cell death (Barker, 2004). This raises the possibility that there are other 
mammalian ligands for p75NTR. Proneurotrophins, the precursors of neurotrophins, have 
been found binding p75NTR with high affinity and triggers cell death at much lower 
concentrations, compared to mature neurotrophins (Lee et al., 2001). It has been 
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demonstrated that proNGF and proBDNF (Teng et al., 2005) are the potent inducers of 
p75NTR-dependent apoptosis in vitro, such as sympathetic neurons, oligodendrocytes, and 
in a vascular smooth muscle cell line (Lee et al., 2001; Nykjaer et al., 2004)  or in vivo, such 
as oligodendrocyte cells and adult corticospinal neurons (Beattie et al., 2002; Harrington et 
al., 2004). There is now evidence that proBDNF functions as an endogenous ligand for 
regulation of long-term depression (LTD) (Woo et al., 2005). Additionally, it has been shown 
that proNGF does not bind TrkA and suggested that proNGF is an apoptotic ligand that is 
specific for p75NTR (Lee et al., 2001). 
 
 
Figure 2.10 The complex consisting of p75NTR and sortilin is essential to mediate pro-
apoptotic signals in response to proneurotrophins. 
 
However, it has been implied that there should have additional membrane proteins required 
for the proneurotrophin-induced cell death in addition to p75NTR, since not all p75NTR-
expressing cells responded to proNGF (Nykjaer et al., 2004). In 2004, Nykjaer et al. reported 
that sortilin, a member of Vps10p-domain receptors, acted as an essential co-receptor to 
p75NTR for proNGF-indeced neuronal cell death (Fig. 2.10). Through crosslinking studies, 
they found that p75NTR and sortilin formed a receptor complex binding proNGF at the cell 
surface. ProNGF directly interacts with the extracellular domain of sortilin via its pro-domain, 
whereas it interacts with p75NTR most likely by the mature domain. The interaction between 
proBDNF and sortilin seems stable and proBDNF appears to be protected from proteolysis or 
degradation via interacting soluble sortilin (Teng et al., 2005). ProBDNF is processed to 24 
kDa and 13 kDa products over 4 h during incubation with plasmin, whereas proBDNF 
exhibits reduced degradation in the form of proBDNF–sortilin complex under comparable 
conditions. The signaling pathway of the p75NTR-sortilin complex has not been defined so 
far, but both receptors appear to be required to transduce the apoptotic effects of proNGF. 
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Blocking the interaction between proNGF and sortilin will inhibit proNGF-induced apoptosis, 
whereas introducing exogenous sortilin to Schwann cells, which normally express only 
p75NTR, will render these cells sensitive to the apoptotic effect of proNGF (Nykjaer et al., 
2004).  
 
2.3.2.4 NgR-Lingo-1-p75NTR complex inhibits the regeneration of neurons after injury 
It is generally known that adult CNS lacks regeneration after injury. Three myelin proteins, 
namely myelin-associated glycoprotein (MAG), Nogo and oligodendrocyte myelin 
glycoprotein (OMgp), have been determined playing important roles in the inhibition of 
neurite outgrowth (Woolf, 2003). Nogo receptor (NgR), a glycosylphosphatidylinositol (GPI) 
anchor receptor, binds the myelin proteins with high affinity. However, NgR alone cannot 
signal any inhibition since it has no intracellular domain (Fournier et al., 2001). In 2002, the 
NgR-p75NTR complex was confirmed by immunoprecipitation from the cells coexpressing 
both receptors (Wang et al., 2002; Wong et al., 2002). Soon after, Lingo-1 was identified to 
bind both NgR and p75NTR via extracellular domains (Mi et al., 2004). Moreover, Mi et al. 
also demonstrated that the NgR-Lingo-1-p75NTR complex was essential in the signal 
transduction of myelin-derived inhibitors (Fig. 2.11).  
 
 
Figure 2.11 The activation of the NgR-Lingo-1-p75NTR complex by myelin proteins 
results in transducing an axon growth inhibition signal.  
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Although the precise mechanism of the NgR-Lingo-1-p75NTR complex in myelin-derived 
inhibition remains to be determined, it has been reported that activation of Ras homologue 
member A (RhoA) appears to act as a key player in inhibiting the regeneration of the CNS. 
Usually, RhoA is maintained in an inactive state in cells binding to Rho guanine dissociation 
inhibitor (Rho-GDI) (Sasaki and Takai, 1998). However, RhoA can be released from Rho-GDI 
as p75NTR binds to Rho-GDI with its fifth helix after myelin activates the NgR-Lingo-1-
p75NTR complex. Thereby, the released RhoA can be activated by guanine exchange 
factors (GEFs), and activate Rho-activated kinase (ROCK), whereupon the growth cone then 
collapses (Yamashita and Tohyama, 2003; He and Koprivica, 2004). Nevertheless, RhoA 
becomes down-regulated when p75NTR binds NTs, resulting in growth cone elongation 
(Gehler et al., 2004). 
 
2.3.3 P75NTR in neuronal disease  
Although p75NTR expression is downregulated in the adult organism, it is significantly re-
expressed under certain pathological conditions of increased neuronal cell death. Emerging 
evidences have shown the linkage between p75NTR and many diseases including 
schizophrenia, cerebral edema Alzheimer’s disease (AD), mechanical damage, focal 
ischemia, axotomy, stroke and amyotrophic lateral sclerosis (Schor, 2005). For example, 
amyloid β (Aβ) peptide accumulates in the brains of AD’s patients and binds to p75NTR to 
induce p75NTR-dependent cell death (Hashimoto et al., 2004). In contrast, Zhang and 
colleagues found that incubation of primary human neurons in culture with Aβ peptide 
resulted in up-regulation of p75NTR and thereby protected neurons against Aβ induced 
toxicity (Zhang et al., 2003). The defined role of p75NTR in neuronal diseases still remains to 
be investigated. 
 
2.4 Aim of this study 
The goal of this study was to generate ER-intrabodies for p75NTR surface knockdown in 
mammalian cells. Based on phage display, scFvs specific to the extracellular domain of 
p75NTR were selected. The isolated scFvs were characterized by antigen binding ELISA, 
immunoblotting, SPR and flow cytometry. ER-intrabodies were constructed fusing the ER 
retention signal KDEL at the C-terminal of p75NTR-specific scFvs. Moreover, a novel 
bicistronic knockdown vector was generated to express the ER-intrabody and farnesylated 
EGFP (EGFP-F). The effects of these p75NTR-specific ER-intrabodies were examined in two 
distinct cell lines, PC12 and NSC19, which both express p75NTR endogenously. A time 
course knockdown experiment was performed in order to determine the kinetics of the 
p75NTR-specific ER-intrabody effect and the unfolded protein response (UPR) during 
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p75NTR surface downregulation process. Finally, mouse hippocampal primary cultures were 
applied to test p75NTR surface knockdown via the ER-intrabodies and dendrite complexities 
of transfected neurons were analyzed by fluorescence microscopy and Sholl analysis. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Technical equipments 
The technical equipments used in this study are listed in Tab. 3.1. 
Table 3.1 Technical equipments  
Equipment class Type Supplier 
Blot apparatus BioRad Trans-Blot Semi-dry SD BioRad, Germany 
Centrifuge Eppendorf 5415D 
Eppendorf 5810R 
Sorvall RC6 plus 
Heraeus Biofuge pico 
Eppendorf AG, Germany 
Eppendorf AG, Germany 
Thermo, USA 
Heraeus, Germany 
Clean bench LaminAir HLB 2472 
HeraSafe 
Heraeus, Germany 
Heraeus, Germany 
Cell culture incubator Kendro Heraeus HeraCell 
Omnilab Memmert Model 100-
800 
Heraeus, Germany 
DNA electrophoresis Model 40-0708 Peqlab, Germany 
Electro-balance Sartorius excellence 
Sartorius analytic 
Sartorius, Germany 
Sartorius, Germany 
Electrophoresis apparatus Electrophoresis power supply 
EPS 601/301 
Mini protean 3 cell 
Amersham, Sweden 
 
Bio-Rad, Germany 
ELISA Reader Tecan Sunrise Tecan, Germany 
ELISA washer Columbus plus Tecan, Germany 
Flow cytometer FC 500 Beckman Coulter, USA 
 BD FACSAriaTM II BD Biosciences, USA 
Microscope Leitz Diavert Leitz, Germany 
 Axioplan 2 microscope with an 
Apotome® 
Zeiss, Germany 
Microtiter plate shaker Microtiter plate shaker Lab4You, Germany 
PCR thermo cycler PTC-200 MJ research, USA 
pH meter Schott Typ CG810 Schott AG, Germany  
Protein purification Äkta prime GE Healthcare, USA 
Sequencing device ABI PRISM 310 Genetic 
Analyzer 
A&B Applied Biosystem 
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Table 3.1 (continued)   
Equipment class Type Supplier 
Spectrophotometer Nano-drop ND-1000 Thermo, USA 
Surface plasmon 
resonance 
Biacore 2000 GE Healthcare, USA 
Thermo-apparatus Thermomixer compact Eppendorf, Germany 
Trans-luminometer iNTAS UV system iNTAS, Germany 
Vortexer VortexGenie2 Scientific Industries, USA 
Ultra-pure water device Arium Sartorius, Germany 
 
3.1.2 Chemicals 
All chemicals were supplied by Amersham, Invitrogen, Firmen Fluka, Merck, Riedel-de Haen, 
Roche Applied Science and Sigma-Aldrich. Enzymes were purchased from New England 
Biolabs and MBI Fermentas.  
 
3.1.3 Buffers and solutions 
The buffers and solutions used in this study are listed in Tab. 3.2. They were either prepared 
with double distilled water (ddH2O) or as indicated. 
Table 3.2 Buffers and solutions 
Buffer and solution Recipe 
5 x Laemmli buffer 10% (w/v) SDS; 50% (v/v) Glycerin; 0.02% (w/v) 
Bromphenol blue; 15% (v/v) β-Mercaptoethanol 
50 x TAE buffer 2 M Tris; 1 M Acetic acid; pH8.0 
Ampicillin solution 100mg/mL Ampicillin  
Cell lysis buffer 1% Nonidet P-40 [IGEPAL CA630 CAT NO.198596 LOT 
No. 9215F (ICN Biomediacals, Inc.)]; 10 mM Tris (pH 7.6); 
150 mM NaCl; 5 mM EDTA; 1 mM PMSF. Protease 
inhibitor added before using: Aprotinin 5μg/mL; Leupeptin 
5μg/mL; Pepstatin 5μg/mL 
Ethidium bromide solution 10mg/mL Ethidium bromide  
Gey’s Balanced Salt Solution 
pH 7.4 (GBSS) 
1.5 mM CaCl2 • 2H2O; 5 mM KCl; 0.22 mM KH2PO4; 1 mM 
MgCl2 • 6H2O; 0.28 MgSO4 • 7H2O; 137 mM NaCl; 2.7 mM 
Na2HCO3; 0.86 mM Na2HPO4; 5.5 mM D-Glucose 
Hank’s Buffered Salt Solution 
(HBSS) 
50 mL 10x HBSS (Invitrogen, Germany); 175 mg NaHCO3; 
147 mg CaCl2• 2H2O; adjusted to 500 mL with ddH2O  
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Table 3.2 (continued)  
Buffer and solution Recipe 
MgCl2-CaCl2 solution 80mM MgCl2; 20mM CaCl2 
PBS 8 g/l NaCl, 0.2 g/l KCl; 1.44 g/l Na2HPO4 • 2H2O; 0.24 g/l 
KH2PO4; pH 7.4 
PBS-T 0.05% Tween20 in PBS 
PE buffer 20% (w/v) sucrose; 50 mM Tris; 1 mM EDTA; pH8 
Solutions for Coomassie 
staining 
Staining solution: 
0.05% (w/v) Coomassie brilliant blue R250; 25% (v/v) 
Isopropanol; 10% (v/v) glycidic acetic acid 
 Destaining solution: 
10% (v/v) glycidic acetic acid 
Solutions for ELISA Coating buffer: 
100 mM NaHCO3, pH 9.6 
FCS/PBS: 
50% (v/v) FCS in PBS 
Developing substrate solutions: 
TMB solution A: 30 mM Potassium citrate; 0.5 mM Citric 
acid; pH 4.1 
TMB solution B: 10 mM Tetramethylbenzidine (TMB); 10% 
(v/v) Acetone; 90% (v/v) Ethanol; 80 mM H2O2 
Stopping solution: 
1N H2SO4 
Solutions for IMAC 10 mM imidazole buffer: 
10 mM imidazole; 20 mM Na2HPO4; 500 mM NaCl 
50 mM imidazole buffer: 
50 mM imidazole; 20 mM Na2HPO4; 500 mM NaCl 
Elution buffer: 
250 mM imidazole; 50 mM Na2HPO4; 300 mM NaCl 
Solutions for SDS-PAGE Acrylamid mix: 
30% (w/v) Acrylamid; 0.8% (w/v) Bisacrylamid 
Ammonium persulfate (APS) solution: 
10% (w/v) APS in dH2O  
Tris-HCl solution: 
(1) 1.5M TrisHCl in dH2O (pH 8.8) 
(2) 1M TrisHCl in dH2O (pH 6.8) 
SDS solution: 
10% (w/v) SDS in ddH2O 
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Table 3.2 (continued)  
Buffer and solution Recipe 
Solutions for SDS-PAGE Running  buffer: 
25 mM Tris-HCl; 192 mM Glycin; 0.1% SDS 
Solutions for SPR Running PBS-T buffer: 
0.005% peroxidase-free Tween20 in PBS 
Coupling buffer: 
10mM acetic acid; 10 mM sodium acetate; pH 4.5 
Regeneration buffer: 
10 mM glycin buffer (pH1.5 or pH2.0) 
Solutions for Western Blot Blocking solution: 
2-3% (w/v) skim milk powder in PBS 
Running buffer: 
25mM Tris; 192mM Glycin 
10x NBT solution: 
70% (v/v) Dimethylformamid; 30mg NBT 
10x BCIP solution: 
100% (v/v) Dimethylformamid; 15mg BCIP 
AP Substrate buffer: 
0.1M Tris; 0.5 mM MgCl2; pH 9.5 
50x DAB solution:  
25 mg/mL DAB diluted in ddH2O 
DAB substrate buffer: 
0.02% cobalt (II) – chloride solution in ddH2O 
 
3.1.4 Medium  
3.1.4.1 Prokaryotes 
All media used for culturing and handling E. coli are shown below. 
 
2 x YT medium 1.6% Bacto-Trypton; 1% Bacto yeast extract; 0.5% NaCl; 
pH7.0 
  
2 x YT Agar 1.5% (w/v) agar in 2 x YT medium 
  
LB medium 10 g/l Bacto-Trypton; 5 g/l Bacto-yeast extract; 10 g/l 
NaCl 
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SOC medium 2% Bacto-Trypton; 0.5% Bacto yeast extract; 0.05% 
NaCl; 10mM MgCl2; 20mM Glucose 
 
3.1.4.2 Eukaryotes 
All reagents and media used for mammalian cell cultures are listed in Tab. 3.3 and Tab. 3.4, 
respectively. 
Table 3.3 Reagents for mammalian cell cultures 
Product Catalog Number Supplier 
Accutase L11-007 PAA, Austria 
B27 supplement 10889038 Gibco, Invitrogen, Germany 
DMEM E15-810 PAA, Austria 
DMSO 4720.1 Carl Roth, Germany 
Fetal calf serum (FCS) 10084-168 Gibco, Invitrogen, USA 
G418 P02-012 PAA, Austria 
GlutaMAX 35050061 Gibco, Invitrogen, Germany 
L-Glutamine M11-004 PAA, Austria 
Neurobasal  21103046 Gibco, Invitrogen, Germany 
Penicillin/streptomycin (P/S) P11-010 PAA, Austria 
Poly-L-Lysine P4707 Sigma, Germany 
RPMI1640 E15-840 PAA, Austria 
Trypsin-EDTA (1x) L11-004 PAA, Austria 
   
 
Table 3.4 Media for mammalian cell cultures 
Medium Recipe 
Medium for HEK 293T cells DMEM; 8% FCS; 1% P/S 
   
Medium for PC12 cells RPMI1640; 10% Horse serum; 5% FCS  
   
Medium for NSC19 cells DMEM, 10% FCS 
  
Medium for dissociated 
hippocampus cultures 
Neurobasal 50 mL; B27 supplement 2 mL; GlutaMAX (200 mM) 
125 µL 
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3.1.5 E. coli strains, eukaryotic cell lines and mouse strain  
All bacterial strains, eukaryotic cell lines and mouse strain are listed in Tab. 3.5 and Tab. 3.6, 
respectively. 
Table 3.5 Bacterial strains 
E. coli strain Genotype Supplier 
DH5α F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1 
tonA 
Invitrogen, Germany 
XL1-Blue-MRF’ K12 strain: _(mcrA)183 _(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F  ´
proAB lacIqZ_M15 Tn10 (Tetr)] 
 
Stratagene, USA 
 
Table 3.6 Eukaryotic cell lines and mouse strain 
Cell line Description Supplier 
HEK 293T Immortalized human embryonic kidney 
cells 
ATCC (CRL-1573) 
PC12 Immortalized rat pheochromocytoma 
cells 
DSMZ (ACC 159) 
NSC19 Neuroblastoma × spinal cord (NSC) 
hybrid cells (Cashman et al., 1992) 
Kind gift from Prof. Brigitte M. 
Jockusch, Zoologisches Institut, 
TU Braunschweig 
Mouse strain C57 Bl/6 Kind gift from Prof. Martin Korte, 
Institute for cellular neurobiology, 
TU Braunschweig 
 
3.1.6 Plasmids  
All plasmids are listed in Tab. 3.7. 
Table 3.7 Plasmids 
Plasmid Description Supplier 
pCMV-hIgG1-Fc-XP Mammalian expression vector Modified from pCMV (Invitrogen, 
USA) 
pCMV/myc/ER Mammalian expression vector Invitrogen, USA 
pOPE101-XP Prokaryotic expression vector (Schmiedl et al., 2000) 
IRAVp968B1065D6 Full length mouse p75NTR RZPD, Germany 
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3.1.7 Oligonucleotides 
All oligonucleotides were synthesized by MWG-Biotech AG (Germany), biomers.net GmbH 
(Germany), or Eurofins MWG Operon (Germany). The list is shown below.  
Table 3.8 Oligonucleotides 
Name Sequence (5’- 3’) 
CZP92 TGC CAT GGC AAA GGA GAC ATG TTC CAC AGG CAT GT 
CZP93 AGA CGC GGC CGC AGG AAT GAG GTT GTC AGC GGT GCC T 
MKpelB-f GCC TAC GGC AGC CGC TGG 
Mkmyc-r GAT CCT CTT CTG AGA TGA G 
CZP1 ACG CGT GCT AGC GCC CCT CTC CCT CCC CCC CCC CTA ACG 
CZP2 ATG GTT GTG GCC ATG GTG TAT ACG TGT TTT TCA AAG GAA AAC 
CAC G 
CZP8 TCG CCA CCA TGG TGA GCA AGG GCG AGG AGC TGT T 
CZP9 ATC CTC TAG ATC AGG AGA GCA CAC ACT TGC AG 
CZP139 ATG TGC GGC CGC AGA GGA CGG T 
CZP143 GGC CGC GCG CAC TCC GAG GTG CAG CTG TTG GAG ACC GGG 
GGA 
CZP144 GGC CGC GCG CAC TCC CAG GTG CAG CTG GTG CAG TCT GGG 
GGA 
CZP145 GGC CGC GCG CAC TCC GAG GTG CAG CTG GTG CAG TCT GGG 
GGA 
AMAP1 ACA GGC GCG CAC TCC CAG GTG CAG CTG GTG CAG TCT 
NS20 CCA GGA GTT CAG GTG CTG 
  
 
3.1.8 Antibodies 
All antibodies are listed in Tab. 3.9. 
Table 3.9 Antibodies 
Antibody Catalog Number Supplier 
Mouse anti-myc (9E10) 
 
 
Hybridoma 
supernatant 
AG Dübel, TU Braunschweig 
mAb mouse anti-His6 11922416001 Roche, Germany 
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Table 3.9 (continued)   
Antibody Catalog Number Supplier 
Goat anti-mouse IgG (Fab 
specific) conjugated with 
horseradish peroxidase (HRP) 
A2304 Sigma, USA 
   
Goat anti-mouse IgG (Fc-specific) 
conjugated with alkaline 
phosphatase (AP) 
 
A2429 Sigma, USA 
mAb mouse anti Penta-His5 HRP 
conjugated 
 
34460 Qiagen, Germany 
mAb mouse anti Penta-His5 34460 Qiagen, Germany 
   
pAb goat anti-mouse IgG (Fc 
specific) HRP conjugated 
A0168 Sigma, USA 
   
mAb mouse anti-p75NTR (MLR2) 
 
Ab61425 abcam, Cambridge, UK 
Recombinant rat TrkA/Fc chimera 
 
1056-TK R&D systems, USA 
goat anti-mouse IgG (Fcγ specific) 
F(ab’)2 fragment allophycocyanin 
(APC) conjugated 
 
115-136-071 Jackson ImmunoResarch, 
Germany 
mAb goat anti-human IgG (Fc 
specific) conjugated with HRP 
 
A0170 Sigma, USA 
pAb rabbit anti-human p75NTR 
(intracellular) 
G3231 Promega 
   
pAb rabbit anti-human p75NTR 
(extracellular) 
 
AB1554 Chemicon 
Goat anti-rabbit IgG (H+L) Cy3 
conjugated  
 
111-165-003 Jackson ImmunoResearch, 
Germany 
Rabbit anti-GAPDH G9545 Sigma, USA 
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Table 3.9 (continued)   
Antibody Catalog Number Supplier 
Rabbit anti-GRP94 G4545 Sigma, USA 
 
Goat anti-rabbit IgG (whole 
molecule) AP conjugated 
 
A9919 
 
Sigma, USA 
 
3.1.9 Softwares 
All softwares are listed in Tab. 3.10. 
Table 3.10 Softwares  
Software Supplier 
Cytomics CXP Beckman Coulter, USA 
 
EXCEL Microsoft, USA 
 
FinchTV 1.3.1  Geospiza, USA 
 
ImageJ National Institutes of Health, USA 
 
Neurolucida and 
Neurolucide Explorer 
Micro bright field, USA 
  
VectorNTI  Invitrogen, USA 
  
 
3.2 Methods 
3.2.1 Methods of molecular biology 
3.2.1.1 Polymerase chain reaction (PCR) 
Phusion DNA polymerase (NEB, USA) or REDTaq polymerase (Sigma, USA) were used to 
amplify the DNA of interest or to identify the cloning of interest, respectively. The PCR 
components and programs were adjusted due to the manufacturer’s instructions. All the 
reactions were accomplished by PTC-200 DNA engine Thermal Cycler. Examples of PCR 
are shown below. Annealing temperature (x) and extension time (y) are calculated for each 
reaction due to primers and DNA length of interest, respectively. 
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PCR components and program with Phusion DNA polymerase: 
Components:   Program: 
5x Phusion HF Buffer  10 μL  1 98 °C 30 s 
10mM dNTPs (200 μM) 1 μL  2 98 °C 10 s 
Forward primer (10 pmol/μL) 2.5 μL  3 x °C 30 s 
Reverse primer (10 pmol/μL) 2.5 μL  4 72 °C y min 
Template DNA (1pg~10ng) 0.2 µL  5 Go to 2 29 Cycles 
Phusion DNA polymerase (2U/μL) 0.5μL  6 72 °C 10 min 
Double destilled water Adjust to 50 µL  7 16 °C  forever 
   8 END  
 
PCR components and program with REDTaq polymerase: 
Components:   Program: 
10x REDTaq Polymerase Buffer 1 μL  1 94 °C 1 min 
10mM dNTPs 200 μM  2 94 °C 1 min 
Forward primer (10 pmol/μL) 0.2 μM  3 x °C 45 s 
Reverse primer (10 pmol/μL) 0.2 μM  4 72 °C y min 
Template DNA One bacterial 
colony picked 
 5 Go to 2 29 Cycles 
REDTaq DNA Polymerase (10 U/μL) 0.3 U  6 72 °C 10 min 
Double destilled water Adjust to 10 µL  7 16 °C  forever 
   8 END  
 
3.2.1.2 Agarose gel electrophoresis 
0.8-1.2% (w/v) agarose gels were prepared in TAE buffer to separate DNA fragments. 
Appropriate amount of agarose was dissolved in TAE buffer and poured into an 
electrophoresis chamber with ethidium bromide (EB) solution in the final concentration of 0.5 
µg/mL. 6x loading dye was mixed with DNA sample. The electrophoresis was performed at 
10 volt/cm for 30-50 min. The agarose gel was photographed under iNTAS UV system. 
 
3.2.1.3 Purification of DNA fragments 
DNA fragments were purified by NucleoSpin Extract II kit (Macherey & Nagel, Germany) after 
PCR, enzymatic restriction or agarose gel electrophoresis. DNA was eluted with ddH2O. 
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3.2.1.4 Enzymatic restriction of DNA 
DNA samples were digested by restriction endonucleases supplied by New England Biolabs 
(NEB, USA) or MBI Fermentas (Germany). Reaction parameters such as buffer, temperature 
and incubation time were varied according to the manufacturer’s instructions. Restriction 
enzyme was added at the last step.  
 
3.2.1.5 Dephosphorylation of DNA fragment  
Removal of the 5'-terminal phosphates from the double-stranded DNA (dsDNA) ends 
prevents vector from self-ligation. 1 µL of Calf Intestinal Alkaline Phosphatase (CIP, NEB, 
USA) was used to dephosphorate about 100 ng of purified DNA fragment with recommend 
buffer. The reaction was performed at 37 °C for 30 min.  
 
3.2.1.6 Ligation of DNA 
DNA fragments were ligated using T4 DNA ligase (Promega, Germany) according to the 
manufacturer’s instruction. The whole reaction system was adjusted to 10µL with ddH2O. The 
reaction was performed at 16 °C overnight.  
 
3.2.1.7 Plasmid construction 
Standard cloning procedures were performed as described (Sambrook et al., 1989). 
Expression vector for antigen production in human embryonic kidney (HEK) 293T cells: 
A mouse p75NTRex-Fc fusion construct was generated by cloning the mouse p75NTR 
extracellular domain via NcoI and NotI into a modified pCMV vector containing the human 
IgG1 Fc domain (Fig. 3.1). 
hIgG1-Fcp75NTRex Poly ACMV
NcoI NotI
 
 
Figure 3.1 Schematic representation of the mammalian expression vector for 
producing antigen for phage display. CMV: CMV immediate early promoter; p75NTRex: the 
extracellular domain of p75NTR; hIgG1-Fc: human IgG1 Fc domain; PolyA: BGH polyadenylation 
sequence.  
Signal 
peptide 
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The cDNA of extracellular domain of mouse p75NTR was obtained from RZPD (German 
Science Centre for Genome Research, Germany) by PCR using primer pair of CZP92 (5’-
TGC CAT GGC AAA GGA GAC ATG TTC CAC AGG CAT GT-3’) and CZP93 (5’-AGA CGC 
GGC CGC AGG AAT GAG GTT GTC AGC GGT GCC T-3’). The human antibody Vκ3 
(hVκ3S) subfamily signal sequence and the mouse antibody heavy chain VH3 (mVH3S) 
subfamily signal sequence containing a synthetic intron were used for expressing the mouse 
p75NTRex-Fc fusion protein in HEK 293T cells. The mammalian expression vector for 
mouse p75NTRex-Fc fusion protein was named as pCMV-mp75NTRex-Fc.  
Expression vectors for scFvs production in E. coli: 
The p75NTR-specific scFvs SH325-A11, SH325-B6 and SH325-G7 were selected from the 
naïve human antibody gene library HAL4 (Kappa) and HAL7 (Lambda) (see chapter 3.2.2.4). 
Oligonucleotides MKpelB-f (5’-GCC TAC GGC AGC CGC TGG-3’) and Mkmyc-r (5’-GAT 
CCT CTT CTG AGA TGA G-3’) were used to obtain the scFv cDNA sequences by PCR. The 
E. coli expression vectors pOPE101-SH325-A11, pOPE101-SH325-B6, and pOPE101-
SH325-G7 were generated by cloning the scFv cDNA sequences into E. coli expression 
vector pOPE101-XP (Hust et al., 2007a)via NcoI/NotI.   
Knockdown vectors: 
The bicistronic knockdown vector encodes the p75NTR-specific ER-intrabody and a 
farnesylated EGFP (EGFP-F) as a reporter gene from a single transcript (Fig. 3.1). 
 
Figure 3.2 Schematic representation of the bicistronic knockdown vector. CMV: CMV 
immediate early promoter; VH: variable domain of heavy chain; VL: variable domain of light chain; 
KDEL: C-terminal ER retention signal; IRES: internal ribosomal entry site; EGFP-F: farnesylated 
enhanced green fluorescent protein; PolyA: BGH polyadenylation sequence. 
 
The cDNA sequences of encephalomyocarditis virus (EMCV) internal ribosomal entry site 
(IRES) element and EGFP-F were obtained by PCR using primer pairs of CZP1 (5’-ACG 
CGT GCT AGC GCC CCT CTC CCT CCC CCC CCC CTA ACG-3’)/CZP2 (5’-ATG GTT GTG 
GCC ATG GTG TAT ACG TGT TTT TCA AAG GAA AAC CAC G-3’) and CZP8 (5’-TCG CCA 
CCA TGG TGA GCA AGG GCG AGG AGC TGT T-3’)/CZP9 (5’-ATC CTC TAG ATC AGG 
AGA GCA CAC ACT TGC AG-3’), and cloned into the knockdown vector via NheI/NcoI and 
NcoI/XbaI, respectively. A sequence of His6 tag and ER retention sequence KDEL were 
EGFP-FVH IRES Poly ACMV VL
BssHII NotI NheI XbaINcoI
 
Signal 
peptide 
Linker KDEL 
His6 
tag 
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constructed at C-terminal of first cistron between NotI and NheI. Three p75NTR-specific 
scFvs were amplified by PCR using the same reverse primer CZP139 (5’-ATG TGC GGC 
CGC AGA GGA CGG T-3’) and three forward primers CZP143 (5’-GGC CGC GCG CAC 
TCC GAG GTG CAG CTG TTG GAG ACC GGG GGA-3’), CZP144 (5’-GGC CGC GCG CAC 
TCC CAG GTG CAG CTG GTG CAG TCT GGG GGA-3’), CZP145 (5’-GGC CGC GCG CAC 
TCC GAG GTG CAG CTG GTG CAG TCT GGG GGA-3’), respectively. The resulting PCR 
products were digested with BssHII and NotI and ligated into the knockdown vectors. The 
generated expression vectors were named pKD-αp75NTR-SH325-A11, pKD-αp75NTR-
SH325-B6, and pKD-αp75NTR-SH325-G7. A sequence of the scFv against the hapten 4-
ethoxymethylene-2-phenyl-2-oxazoline-5-one (phOx) was amplified by PCR using AMAP1 
(5’-ACA GGC GCG CAC TCC CAG GTG CAG CTG GTG CAG TCT-3’) and NS20 (5’-CCA 
GGA GTT CAG GTG CTG-3’). The p75NTR-specific scFv was substituted with the amplified 
phOx specific scFv in the knockdown vector and the generated expression vector was 
named pCMV-αphOx-KDEL. This vector was used as a control in later knockdown 
experiments. 
 
3.2.2 Microbiological methods 
3.2.2.1 Glycerol stocks 
For long-term storage of bacteria, liquid culture was inoculated from a single colony and 
incubated in LB medium containing appropriate antibiotics at 37°C with 250 rpm overnight 
shaking. Freshly grown bacterial suspension was adjusted to 30% (w/v) final concentration 
with sterile glycerol and shock frozen in liquid nitrogen. The glycerol stocks were stored at -
80°C. 
 
3.2.2.2 Preparation of chemical competent E. coli 
E. coli DH5α or XL1-Blue from glycerol storage at -80 °C was inoculated into 10 mL of LB 
medium without any antibiotic and then incubated at 37 °C with shaking 250 rpm overnight. 
1mL of this overnight pre-culture was inoculated into 200 mL of pre-warmed LB medium in a 
sterilized flask, and inocubated at 37 °C, 250 rpm until the O.D.600 reached 0.4-0.6. Culture 
was collected into sterile ice-cold 50 mL polypropylene tubes. After cooled on ice for 10-15 
min, the culture was centrifuged at 2700 x g for 5 min at 4 °C and the supernatant was 
carefully decanted. Pellet was resuspended by swirling or gentle vortexing in 30 mL ice-cold 
MgCl2-CaCl2 solution (80 mM MgCl2, 20 mM CaCl2).  Subsequently, the mixture was 
centrifuged at 2700 x g, 4 °C for 5 min and decanted the supernatant carefully. The pellet 
was resuspended by swirling or gentle vortexing in 2 mL ice-cold 0.1 M CaCl2 and glycerin 
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was added in a final dilution of 15%. These competent E. coli were divided into aliquots 
(120μL), shock frozen using liquid nitrogen, and stored at -80°C. 
 
3.2.2.3 Transformation of E. coli 
Chemical competent E. coli (~60 µL) was placed on ice for 10 min for thawing. 5 µL of 
ligation complex was mixed with the pre-cold competent E. coli and incubated on ice for 30 
min. The mixture was transferred to 42 °C for 90 s and then placed on ice for 3 min for 
recovery. 500 µL of pre-warmed SOC medium was added into the mixture and incubated at 
37°C, 800 rpm for 50 min. 100-200 µL culture was pipetted and spread gently on an agar 
plate with ampicillin. The agar plate was incubated with upside down at 37°C overnight after 
it was naturally dried. 
 
3.2.2.4 Selection of recombinant scFvs against p75NTR extracellular domain 
ScFvs against the p75NTR extracellular domain were selected from the naïve human 
antibody gene library HAL4 (Kappa) and HAL7 (Lambda) (Hust et al., 2007b). The library 
was packaged using Hyperphage (Rondot et al., 2001; Soltes et al., 2007; Kugler et al., 2008) 
to get polyvalent display and mixed before panning. The panning and selection was 
performed as described (Hust et al., 2007c). The p75NTRex-Fc fusion protein was used as 
antigen for the panning procedure. Human IgG1 Fc (N protein SL standard, DADE Behring, 
Germany) was also used for preincubation of the library and for competition during the 
panning procedure to omit the selection of binders specific to human IgG1 Fc domain. 
 
3.2.2.5 Production of soluble scFvs in E. coli 
Soluble scFvs were produced in shaking flasks using the E. coli strain XL1-Blue MRF’ 
according to the procedure previously described (Dübel et al., 1992). 300 mL of 2xYT 
medium supplemented with 100 µg/mL glucose and 100 µg/mL ampicillin was inoculated with 
an overnight culture and the O.D.600 was adjusted to be lower than 0.1. The inoculated 
culture was cultured at 37 °C and 250 rpm until O.D.600 was about 0.5. Expression induction 
was initiated by isopropyl-beta-D-thiogalacto-pyranoside (IPTG) adjusting to the final 
concentration of 50 µM. After shaking for 3 hr at 30 °C, bacteria were harvested by 5,000 rpm 
for 5 min. The pellets were resuspended in 1/10 culture volume ice cold PE buffer and 
incubated for 20 min on ice with short vortexing every 5 min. The bacteria were pelleted for 
30 min at 16,000 rpm, 4 °C. The expressed scFvs were purified as described in chapter 
3.2.3.2.  
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3.2.3 Biochemical methods 
3.2.3.1 Plasmid DNA preparation from E. coli  
For miniprep, plasmid DNA was prepared from E. coli using NucleoSpin Plasmid kit 
(Macherey & Nagel, Germany). Midipreps of plasmid DNA was performed by Sigma high 
performance Midi Plasmid Purification Kit (Sigma, USA) if the DNA was used for transfection 
of mammalian cells. Plasmid DNA concentration and purity were determined by absorption 
measurement with 260/280 nm in Nanodrop 2000. The DNA sequence was determined by 
Big Dye® Terminator v1.1 Cycle Sequencing kit or GATC Biotech AG (Germany).  
 
3.2.3.2 Immobilized metal affinity chromatography (IMAC) purification for soluble 
scFvs 
Immobilized metal affinity chromatography (IMAC) was used for soluble scFv purifications. 
Chromatography was performed using 0.5 mL Chelating SepharoseTM Fast Flow (GE 
Healthcare, Germany) according to the manufacturer’s instruction. Supernatant (periplasmic 
fraction) was collected and dialysed against PBS at 4 °C overnight. The dialysed periplasmic 
fraction was adjusted to binding condition (10 mM imidazole, 20 mM Na2HPO4, 500 mM NaCl) 
before loading. After loading, sepharose was washed with 10 mM imidazole buffer once, 50 
mM imidazole buffer twice and PBS once. The soluble scFvs were eluted by elution buffer 
(250 mM imidazole, 50 mM Na2HPO4, 300 mM NaCl) and stored at -80 °C.   
 
3.2.3.3 Enzyme-linked immunosorbent assay (ELISA) 
Antigen binding ELISA 
In the antigen binding ELISA, N protein SL standard, BSA, and 5 fusion proteins containing 
the same hIgG1 Fc domain and different neuronal receptor domains were used as controls. 
A BD 96-well plate (BD, USA) was coated with 100 ng of p75NTRex-Fc fusion protein or 
controls in 100 µL of PBS per well at 4 °C overnight. The coated plate was blocked with 100 
µL of FCS per well for 1.5 hr at 37 °C and then 3x washed with PBST. The plate was 
subsequently incubated with 250 ng of the p75NTR-specific scFvs (see chapter 3.2.2.4) for 
1.5 hr at 37 °C. After 3x washing with PBST, these scFvs were detected by mAb anti-myc tag 
(9E10 hybridoma, 1:500) and goat anti-mouse IgG (Fab specific) conjugated with 
horseradish peroxidase (HRP) (1:5,000). Signals were developed with TMB (3,3’,5,5’-
tetramethylbenzidine) substrate and stopped by 100 µL of 1N sulphuric acid per well. The 
absorbances at 450 nm with subtracting the 620 nm reference was measured by a SUNRISE 
microtiter plate reader. 
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Competition ELISA 
In the competition ELISA, BD 96-well plates were coated with 100 ng of the p75NTRex-Fc 
fusion protein (see chapter 3.2.4.8) for each well overnight at 4 °C and blocked with FCS for 
1.5 hr at 37 °C. The p75NTR-specific scFvs with serial dilution were added. After incubated 
for 1.5 hr at 37 °C, the plates were 3x washed with PBST. The plates were again incubated 
with mAb mouse anti-p75NTR (MLR2, 1:5,000) for 1.5 hr at 37 °C and 3x washed with PBST. 
The scFvs and mAb mouse anti-p75NTR (MLR2) were detected by mAb mouse anti Penta-
His HRP conjugated (1:5,000) and pAb goat anti-mouse IgG (Fc specific) HRP conjugated 
(1:5,000) in corresponding plates respectively. Non-specific bindings of the HRP conjugated 
detection antibodies were assessed by negative control wells consisted of the scFvs 
combined with the pAb goat anti-mouse IgG (Fc specific) HRP conjugated or mAb mouse 
anti-p75NTR (MLR2) combined with mAb mouse anti Penta-His HRP conjugated. Signals 
were developed and measured as described in antigen binding ELISA. 
 
3.2.3.4 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation and stacking gels were prepared as the components listed in Tab. 3.11 according 
to the sizes of samples to be separated. The separation gel was cast between the glass 
plates with Bio-Rad Mini Protean and overlayed by isopropanol. After gel polymerization, the 
isopropanol was removed, and the stacking gel was cast into the gel chamber with an 
appropriate comb inserted. Samples were denatured with appropriate volume of 5 x Laemmli 
buffer at 95 °C for 10 min before loaded to SDS-PAGE gel. Gel electrophoresis was 
performed under constant 200 volt for 45 min.  
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Table 3.11 Components for preparation of SDS-PAGE.  
 Seperation gel Stacking gel 
 10% 12% 4% 
ddH2O 1.6mL 1.3mL 1.0mL 
1.5M Tris-HCl, 
pH8.8 
1mL 1mL  
1.5M Tris-HCl, 
pH6.8 
  0.20mL 
10% (w/v) SDS 40µL 40µL 15µL 
Acrylamide/(30%, 
w/v) 
1.3mL 1.6mL 0.26mL 
10% (w/v) APS 40µL 40µL 15µL 
TEMED 2µL 2µL 2µL 
Total volume 4mL 4mL 1.5mL 
 
3.2.3.5 Coomassie Blue staining 
Proteins separated by SDS-PAGE can be detected by coomassie blue solution for 2-3 hr with 
gently rocking. Gels were destained in 10% acetic acid solution overnight.  
 
3.2.3.6 Western blot 
One piece of PVDF membrane was saturated with methanol and two pieces of filter papers 
was saturated with PAGE running buffer without SDS. The transfer sandwich was positioned 
by placing the first filter paper, the membrane, the gel and then the second filter paper in the 
order from bottom to top. The process of protein transfer was executed by Bio-Rad semi-dry 
cell under constant voltage of 20V for 45min.  
 
3.2.3.7 Immunostain 
Detection of the p75NTRex-Fc fusion protein production 
The p75NTRex-Fc elution fractions purified by ÄktaPrime (see chapter 3.2.4.8) were 
separated by SDS-FAGE and blotted onto a PVDF membrane. The membrane was blocked 
with 2% (w/v) skim milk powder PBST at 4 °C overnight. After washing with PBST, the 
membrane was incubated with goat anti-human IgG (Fc specific) HRP conjugated (1:10,000) 
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for 1 hr at RT. After 3x washing with PBST, the membrane was developed in DAB substrate 
for about 10-20 min. 
Detection of intracellular expressions of the p75NTR-specific scFvs  
To detect the intracellular expressions of p75NTR-specific scFvs, transiently transfected 
PC12 cell lysates (see chapter 3.2.4.7) were prepared and blotted to a PVDF membrane. 
The membrane was blocked with 2% (w/v) skim milk powder PBST at 4 °C overnight. The 
membrane was incubated with mouse anti-His5 (1:2,000) for 1 hr at RT and followed by 3x 
washing with PBST. The membrane was subsequently incubated with goat anti-mouse IgG 
(Fab-specific) AP conjugated (1:5,000) for 1 hr at RT. Bound antibodies were visualized by 
NBT/BCIP substrate for about 10-20 min.  
Determination of unfolded protein response (UPR) 
With intent to determine the activation of UPR, transiently transfected PC12 cells from 
different time points (2-8 days) were sorted by BD FACSAriaTM II based on the EGFP-F 
fluorescence (see chapter 3.2.4.6). Cell extracts of the sorted cells were blotted onto a PVDF 
membrane. After blocking with 2% (w/v) skim milk powder PBST at 4 °C overnight, the 
membrane was incubated with rabbit anti-GRP94 (1:1,000) and rabbit anti-GAPDH (1:5,000) 
for 1 hr at RT, separately. After 3x washing with PBST, the membrane was subsequently 
incubated with goat anti-rabbit IgG AP conjugated antibody (1:5,000) for 1 hr at RT. Bound 
antibodies were visualized by NBT/BCIP substrate for about 10-20 min.  
  
3.2.3.8 Surface plasmon resonance (SPR) 
The binding kinetics of scFvs was measured by surface plasmon resonance using a 
Biacore2000 and a CM5 chip (Biacore, Uppsala, Sweden). The antigen p75NTRex-Fc and 
control rat TrkAex-Fc (R&D systems, USA) were separately coupled on flow cells via amine 
coupling according to the manufacturer’s instructions. The binding experiment was performed 
at the flow rate of 30 µL/min using PBST (0.005% peroxidase-free Tween20) at RT. Chip 
regenerations were done by 10 mM glycin buffers (pH1.5 or pH2.0). The p75NTR-specific 
scFvs with the concentrations from 2.5 nM to 200 nM were injected with an association time 
of 5 min and a disassociation time of 10 min. Curve fittings were done using 1:1 binding with 
drifting baseline.  
 
  Materials and methods 
39 
 
3.2.4 Cellular methods 
3.2.4.1 Cell cultures 
Human embryonic kidney (HEK) 293T cell line was cultured in Dulbecco modified Eagle 
medium (DMEM)/high glucose (4.5 g/L) and L-glutamine (2 mM) supplemented with 8% (v/v) 
fetal calf serum (FCS) and 1% (v/v) penicillin/streptomycin, and cultivated at 37 °C in a 7% 
CO2 incubator.  
Rat pheochromocytoma PC12 cell line was cultured in RPMI 1640/L-glutamine (2 mM) 
supplemented with 10% horse serum (HS) and 5% FCS.  
NSC19 cells were maintained in DMEM/high glucose (4.5 g/L) and L-glutamine (2 mM) 
supplemented with 10% (v/v) FCS. PC12 and NSC19 cells were cultivated at 37 °C in a 5% 
CO2 incubator.  
Cells were passaged in every 2-3 days. Cells were shortly rinsed with PBS and incubated 
with trypsine-EDTA until the cells detached from the bottom of cell culture plates. The 
reaction was stopped by FCS-containing medium. Cells were resuspended in culture medium 
and seeded in 1:10 (for HEK 293T) or 1:2 (for PC12 and NSC19) dilutions. Culture dishes 
and plates were coated with poly-L-lysine for PC12 before use. 
 
3.2.4.2 Freezing and thawing of cells 
For long-term storage, the cells were harvested by trypsine-EDTA and resuspended in 
freezing medium (10% DMSO and 20% FCS in relevant culture medium) for cryopreservation 
in 2 mL polypropylene cryo-tubes. To allow a slow and gradual freezing, the tubes were 
stored at -80°C in a closed styrofoam container for one day. The tubes were consequently 
transferred to liquid nitrogen. Before use, frozen cells were thawed in a 37°C water bath for 
1-2 min and were quickly seeded in pre-warmed appropriate medium. 
 
3.2.4.3 Cell counting 
Cells were pipetted up and down for several times after tyripsinization in order to make cells 
as single cell suspension. To distinguish between living and dead cell, cells were 1:1 diluted 
in Trypan Blue dye. Living and dead cells were counted in a hemocytometer and the total cell 
amount was calculated. 
 
  Materials and methods 
40 
 
3.2.4.4 Transient transfection 
HEK 293T cells were transiently transfected using HEKFectin (Bio-Rad, Germany), while 
PC12 and NSC19 cells were transiently transfected using magnetofection via NeuroMag 
(OzBiosciences, France) according to the supplier’s instructions. Culture plates needed to be 
coated by poly-L-lysine before seeding PC12 cells. Tab. 3.12 lists the reagent quantities for 
different transfections. 
Table 3.12 Reagent Quantities for different transfections. 
Reagent 
6-well 10 cm plate 
DNA [μg] Reagent [μL] DNA [μg] Reagent [μL] 
HEKfectin   10 40 
NeuroMag 4 14   
 
3.2.4.5 Flow cytometry  
2 x 105 of PC12 or NSC19 cells were transferred into a FACS tube (Greiner, Germany). Cells 
were washed with FACS buffer (5mM EDTA, 2% FCS in PBS) and centrifuged at 300 x g for 
5 min at 4 °C. The cell pellets were resuspended in 100 µL of mAb mouse anti-p75NTR 
(MLR2, 1:200) solution or 250 ng of the p75NTR-specific scFvs in 100 µL volume, and then 
incubated for 1 hr on ice. The cell pellets stained by the p75NTR-specific scFvs were washed 
and subsequently resuspended with mAb mouse anti-His6 (1:100) in 100 µL volume, 
incubating for 30 min on ice. Afterwards, all pre-stained cells were washed and incubated in 
100 µL of goat anti-mouse IgG (Fcγ specific) F(ab’)
2 fragment allophycocyanin (APC) 
conjugated (1:200) for 30 min on ice. Finally, after two washing steps cells were resuspended 
in 500 µL of FACS buffer and kept on ice until analysis by flow cytometry using Beckman 
Coulter FC500. Data were analyzed by CXP analysis software. Unspecific bindings were 
excluded by staining cells with secondary antibody alone.   
 
3.2.4.6 Fluorescence assisted cell sorting (FACS) 
PC12 cells were transiently transfected with the knockdown vectors (see chapter 3.2.1.7) by 
NeuroMag. The cells from different time points (2-8 days) were trypsinized and resuspended 
in FACS buffer. Based on the EGFP-F expression from the knockdown transcripts, cells were 
sorted by BD FACSAriaTM II. Only transfected cells in single suspension were interested to be 
harvested with appropriate gates. An example for creating the sorting gates was shown 
below (Fig 3.3).  
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Figure 3.3 An example of cell sorting based on the EGFP fluorescence.  
 
According to the height (H) and area (A) of forward scatter (FSC) and side scatter (SSC), 
gates of P1, P2, and P3 were built for the living cells in single suspension. The transfected 
cells were subsequently gated by P4 due to EGFP-F fluorescence. Finally, sorted cells were 
identified by flow cytometry, and the living and dead cells were indicated by gate P5 and P6, 
respectively. 
 
3.2.4.7 Preparation of cell extracts 
Cells were harvested after transient transfection. After 2x washing with pre-cold PBS, the 
cells were centrifuged at 1,200 rpm for 5 min. Appropriated amount of lysis buffer was used 
to lyse cells. After incubated on ice for 30 min, the cells were centrifuged at 4 °C, 12,000 rpm 
for 10 min. The supernatant was collected and stored at -20 °C until analysis.  
 
3.2.4.8 Production of the p75NTRex-Fc fusion protein 
Production of the p75NTRex-Fc fusion protein was done in HEK293T cells. 24 hr before 
transfection, HEK293T cells were seeded onto a 10-cm petri dish using DMEM/high glucose 
supplemented with 1% penicillin/streptomycin and 8% FCS. HEK293T cells were transfected 
by the plasmid of pCMV-mp75NTRex-Fc using HEKFectin according to the manufacturer’s 
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recommendations. Media were changed to DMEM/high glucose supplemented with 1% 
penicillin/streptomycin and 4% low bovine IgG level FCS (PAA, Germany) 24 hr after 
transfection. Expressed p75NTRex-Fc fusion protein was collected in the supernatant every 
48 hr for 14 days and purified by affinity chromatography using a HiTrapTM 1 mL protein A HP 
column on an ÄktaPrime system according to manufacturer’s instructions. Briefly, before 
loading the filtered samples, column was equilibrated with 20 column volumes binding buffer 
(20 mM sodium phosphate, pH7.0). The column was thoroughly washed with 100 mM citrate 
buffer (pH5.0) after sample loading. In the end, the p75NTRex-Fc fusion protein was eluted 
by 100 mM pH shift citrate buffer (pH2.5), followed by immediate neutralization of 1 M Tris 
buffer (pH9.0).  
 
3.2.5 Methods related to mouse hippocampal primary cultures   
3.2.5.1 Primary culture preparation  
Primary cultures of mouse hippocampal neurons were prepared using mice (C57 Bl/6) 
embryonic day E18. Embryos were decapitated and the brains were kept in ice cold Gey’s 
balanced salt solution (GBSS) supplemented with glucose. Tissue was dissociated by 30 min 
incubation in trypsin followed by mechanical disruption using a Pasteur pipette. Cells were 
plated at high density (105) on poly-L-lysine coated cover slips (13 mm) and kept in 
Neurobasal medium (Gibco) supplemented with 2% B27 (Gibco) and 0.5 mM Glutamax at 
37 °C, 5% CO2 and 99% humidity.  
 
3.2.5.2 Transfection of primary hippocampal neurons 
Primary hippocampal neurons were transfected at 7 DIV using Lipofectamine2000® 
(Invitrogen, Germany) according to the manufacturer’s instruction. Half of the media was 
changed one day prior to transfection and kept at 4 °C. 0.8 µg of DNA was mixed with 2 µL of 
Lipofectamine in Neurobasal medium for each well. The medium was changed 50 min after 
transfection and replaced by half old and half new medium. 
 
3.2.5.3 Immunocytochemistry 
The immunostraining of primary hippocampal cultures was performed at RT. Four days after 
transfection, media were aspirated from the wells and primary hippocampal cultures (11 DIV) 
were incubated with pAb rabbit anti-human p75NTR (extracellular, 1:1,000) or pAb rabbit 
anti-human p75NTR (intracellular, 1:500) that were diluted in HBSS for 15 min. After washing 
with HBSS for 5 min, cultures were fixed with pre-cold 4% paraformaldehyde at 4 °C for 15 
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min and followed by three 20-min washing steps with PBS. The secondy antibody, goat anti-
rabbit IgG Cy3 conjugated (1:500), was diluted in PBS and incubated with primary 
hippocampal cultures for 30 min at RT. Subsequently, two 15-min PBS washing steps were 
performed and the coverslips were mounted upside down on slides. After drying for 30 min at 
RT, culture slides were preserved at 4 °C until analysis by microscopy. 
 
3.2.5.4 Sholl analysis 
Primary hippocampal neurons were imaged using an Axioplan 2 Microscope equipped with 
an Apotome® controlled by the Axiovision® software. Only pyramidal neurons were 
considered due to their morphologies. Plain fluorescence images of hippocampal neurons 
were acquired by a 20x 0.8 NA Plan-APO objective (Zeiss, Germany). 
Dendritic complexity of neuron was evaluated using Neurolucida® and Neurolucide Explorer 
software (Micro bright field, USA) for Sholl analysis (Sholl, 1953). Sholl analysis calculated 
the total number of dendrite crossings as an objective measurement of the total dendrite 
complexity. In brief, a series of concentric circles with 10 µm interval was set around the 
neuronal soma. Based on these circles, the number of neurites crossing each circle was 
counted. A statistical analysis of obtained values was carried out by Microsoft Excel using a 
paired student’s t-test (2-tailed and 2-sample unequal variance). Significance was set at 
p<0.05.    
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4 Results 
4.1 Production of p75NTRex-Fc fusion protein as antigen for phage display  
The antigen p75NTRex-Fc was produced in order to isolate p75NTR-specific scFvs by phage 
display. Since p75NTR is a 75 kDa single-pass type I membrane protein (Swiss-Prot: 
#Q9Z0W1), its extracellular domain is firstly translocated in the ER of mammalian cells. To 
retain p75NTR in the cells, it is necessary to generate scFvs against the extracellular domain 
of p75NTR. The sequence of mouse p75NTR extracellular domain (a kind gift from RZPD, 
Germany) was fused to human IgG1 Fc domain to construct the p75NTRex-Fc (Fig. 3.1). 
HEK 293T cells were used to produce p75NTRex-Fc fusion proteins and the produced 
proteins were subsequently purified by affinity chromatography. The chromatogram of 
purification was illustrated in Fig. 4.1. 
 
 
Figure 4.1 Purification of the p75NTRex-Fc fusion protein using HiTrapTM 1 mL protein 
A HP column. Fraction numbers are marked in read.  
 
In order to determine the produced p75NTRex-Fc fusion protein, samples from nine elution 
fractions (F24-32) and one washing fraction (F6) were analyzed by immunoblotting (Fig. 4.2). 
Due to the glycosylation of p75NTR (Gong et al., 2008) and IgG1 Fc domain (Lund et al., 
1996; Jefferis et al., 1998), p75NTRex-Fc fusion protein migrated to ca. 100 kDa on the 
membrane. Concentrations of elution fractions were determined by human capture ELISA 
(data not shown).  
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Figure 4.2 Immunoblot of the purified fractions (F6, F24-32) of p75NTRex-Fc fusion 
protein. The p75NTRex-Fc elution fractions were obtained from ÄktaPrime purification. The 
membrane was incubated with goat anti-human IgG (Fc specific) HRP conjugated (1:10,000) for 1 hr 
at RT and developed in DAB substrate. M stands for protein marker. 
 
4.2 Selection of recombinant scFvs against the extracellular domain of p75NTR 
by phage display 
Phage display technology was applied to isolate antibody fragments against the extracellular 
domain of p75NTR. The purified p75NTRex-Fc fusion protein was used as antigen for 
panning. The naïve human antibody gene libraries HAL4 (Kappa) and HAL7 (Lambda) were 
employed. HAL4/7 libraries were established based on the phagemid vector pHAL14 that 
expressed antibody fragments as pIII fusion proteins containing a His6-tag and a myc-tag 
(Hust et al., 2007b; Kirsch et al., 2008; Schütte et al., 2009).  
 
Figure 4.3 Identification of soluble monoclonal scFvs obtained from panning by ELISA. 
100 ng of p75NTRex-Fc (shown in dark blue) and 100 ng of N protein SL standard (used as negative 
control, shown in red) were immobilized per well respectively. Soluble monoclonal scFvs were added 
after the antigen-coated plates were blocked with MPBST for 2 hr. Bound scFvs were detected using 
mAb anti-myc tag (9E10 hybridoma, 1:500) and goat anti-mouse IgG (Fab specific) HRP conjugated 
(1:5,000). Positions H9 and H12 were immobilized with 100 ng of lysozyme and incubated with anti-
lysozyme scFv (SH102-10) served as positive controls. 
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In order to avoid isolating scFvs against human IgG1-Fc portion, N protein standard SL 
(Dade Benring, Germany) was used as competitor during panning procedure. The panning 
procedure was kindly performed by Saskia Helmsing (Institute for biochemistry and 
biotechnology, TU Braunschweig). After three rounds of panning and selection, single clones 
were isolated. Soluble monoclonal scFvs were produced in E. coli cultured in microtiter plates 
and assessed for their binding abilities to the immobilized p75NTRex-Fc fusion protein by 
ELISA (Fig. 4.3). ScFvs that bound to the p75NTRex-Fc fusion protein but not N protein SL 
standard were considered as positive binders (signal:noise ratios were greater than 40).  
Out of the positive binders, three unique p75NTR-specific scFvs were finally isolated from the 
human antibody gene library HAL4/7 after DNA sequencing (Tab. 4.1). These scFvs were 
named as SH325-A11, SH325-B6, and SH325-G7. Their sequences were analyzed based 
on the integrative database of germline variable genes from the immunoglobulin loci of 
human (VBASE2). The VH of all three antibodies consisted of a VH3 germline gene. The 
variable light chains were only lambda chains in all three cases, but the V genes were 
derived from different germline genes.  
 
Table 4.1 P75NTR-specific scFvs isolated by phage display. 
Antibody 
clone 
VH VL 
V D J V J 
SH325-A11 IGHV3-23*01 IGHD6-13*01 IGHJ4*02 IGLV6 IGLJ3*02 
SH325-B6 IGHV3 IGHD6-19*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01 
SH325-G7 IGHV3 IGHD2-15*01 IGHJ3*02 IGLV1-44*01 IGLJ3*02 
The names of gene segments are given based on VBASE2. V: variable gene; D: diversity gene 
segment; J: joining gene segment.  
 
4.3 Characterization of the p75NTR-specific scFvs 
For the efficient production of the p75NTR-specific scFvs, the scFv cDNA sequences were 
constructed into the E. coli expression vector pOPE101-XP (Hust et al., 2007a). The 
expression vector of pOPE101-XP was modified from pOPE101-215yol (Schmiedl et al., 
2000) and contained a myc tag and a His6-tag for detection and purification. The p75NTR-
specific scFvs were produced by periplasmic expression in E. coli and purified using IMAC. 
The concentrations of the purified scFvs were determined by SDS-PAGE (Fig. 4.4) in 
comparison with serial diluted scFv standard TM44 C7.3 (kindly provided by Dr. Torsten 
Meyer, Institute for Biochemistry and Biotechnology, TU Braunschweig). The concentrations 
were calculated as 12 µg/mL, 12 µg/mL and 11 µg/mL for SH325-A11, SH325-B6 and 
SH325-G7, respectively.  
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Figure 4.4 Concentration determination for the purified p75NTR-specific scFvs by 
SDS-PAGE. Serial diluted scFv standard TM44 C7.3 and purified p75NTR-specific scFvs were 
separated by reducing SDS-PAGE and stained with coomassie blue. M stands for protein marker. 
 
4.3.1 The p75NTR-specific scFvs do not cross react with other neuronal surface 
proteins 
Potential cross-reactivities of the p75NTR-specific scFvs with human IgG1 Fc domain and 
other neuronal surface proteins were investigated by antigen binding ELISA. In addition to N 
protein SL standard and BSA, five different human IgG1 Fc fusion proteins were used as 
negative controls, including rat TrkAex-Fc, rat TrkBex-Fc, mouse NgRex-Fc, mouse and 
human APPex-Fc. These recombinant proteins contained the extracellular portions of 
different neuronal proteins that are normally expressed by neurons. Moreover, the human 
IgG1 Fc domain used in these recombinant proteins is identical to that in p75NTRex-Fc. 
 
 
Figure 4.5 Cross-reactivities of the p75NTR-specific scFvs were determined by antigen 
binding ELISA. 100 ng of mouse p75NTRex-Fc (shown in dark blue), rat TrkAex-Fc, rat TrkBex-Fc, 
mouse NgRex-Fc, mouse or human APPex-Fc, N protein SL standard or BSA were immobilized in the 
plate for each well. The purified scFvs were added after the antigen-coated plates were blocked with 
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MPBST for 2 hr. Bound scFvs were detected using mAb anti-myc tag (9E10 hybridoma, 1:500) and 
goat anti-mouse IgG (Fab specific) HRP conjugated (1:5,000).  
 
4.3.2 The p75NTR-specific scFvs bind to p75NTR with nanomolar affinities 
Antibody affinity is essential for its application both in vitro and in vivo. Therefore, binding 
kinetics of the p75NTR-specific scFvs to the solid phase immobilized p75NTRex-Fc fusion 
protein was determined by SPR (Fig. 4.6). 
 
Figure 4.6 Determination of binding kinetics of the p75NTR-specific scFvs by SPR. The 
antigen p75NTRex-Fc and control protein rat TrkAex-Fc were separately coupled on flow cells via 
amine coupling. The p75NTR-specific scFvs with the concentrations from 2.5 nM to 200 nM were 
injected with an association time of 5 min and a disassociation time of 10 min. Curve fittings were done 
using 1:1 binding with drifting baseline. Mass transfer limitations were not present at this flow rate of 
30 µL/min. 
 
Recombinant rat TrkAex-Fc fusion protein was coupled on flow cells as the control to the 
p75NTRex-Fc. The binding experiment was performed at the flow rate of 30 µL/min using 
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peroxidase-free PBST and mass transfer limitations were not present at that flow rate. The 
p75NTR-specific scFvs with various concentrations from 2.5 nM to 200 nM were injected with 
an association time of 5 min and a dissociation time of 10 min. The affinities were detected in 
the range of nanomolar for all scFvs and the highest affinity was shown by SH325-A11 (see 
Tab. 4.2). 
 
Table 4.2 Binding kinetics of the p75NTR-specific scFvs (ka, kd, KD) determined by 
surface plasmon resonance. 
 Ka (1/M•s) kd (1/s) KD (M) Rmax (RU) Χ
2 
SH325-A11 2.44 x 105 1.57 x 10-3 6.5 x 10-9 156 2.31 
SH325-B6 4.45 x 105 1.74 x 10-3 3.9 x 10-9 162 4.43 
SH325-G7 1.08 x 105 4.22 x 10-3 3.9 x 10-8 180 0.24 
 
4.3.3 Native p75NTR can be recognized by the p75NTR-specific scFvs 
The p75NTR-specific scFvs need to neutralize p75NTR in the ER of living cells in this study. 
Therefore, it is crucial to verify that the p75NTR-specific scFvs bind to native p75NTR, in 
addition to the recombinant p75NTR immobilized on solid phase.  
 
Figure 4.7 The p75NTR-specific scFvs recognize native p75NTR on PC12 cell surface. 
PC12 or HEK293T cells were stained with 250 ng of the p75NTR-specific scFvs (SH325-A11, SH325-
B6, SH325-G7). Bound scFvs were detected by mAb mouse anti-His6 (1:100) followed by goat anti-
mouse IgG (Fcγ specific) F(ab’)
2
 fragment APC conjugated (1:200). The p75NTR surface expression 
on PC12 cells was determined by staining PC12 and HEK293T cells with the mAb mouse anti-
p75NTR (MLR2, 1:200) followed by goat anti-mouse IgG (Fcγ specific) F(ab’)
2
 fragment APC 
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(p75NTR-positive) 
FL4=APC 
SH325-A11 SH325-B6 SH325-G7 MLR2 
HEK293T        
(p75NTR-negative) 
E
v
e
n
ts
 
  Results 
50 
 
conjugated (1:200). The blue histograms represent the mAb mouse anti-p75NTR (MLR2) or the 
p75NTR-specific scFvs staining PC12 cells (upper row) and HEK 293T cells (lower row). The white 
histograms represent the controls stained with goat anti-mouse IgG (Fcγ specific) F(ab’)
2
 fragment 
APC conjugated alone (MLR2 line) or αphOx scFv (rest lines) followed by mAb mouse anti-His6 and 
goat anti-mouse IgG (Fcγ specific) F(ab’)
2
 fragment APC conjugated.  
 
Rat pheochromocytoma PC12 cells are neuron-like cells that endogenously express p75NTR 
(Ip et al., 1993). The p75NTR expression on the PC12 cell surface was proved using the 
commercial mAb mouse anti-p75NTR (MLR2). Equal amount of cells were incubated with the 
p75NTR-specific scFvs and bound scFvs were analyzed by detecting the His6-tag in flow 
cytometry (Fig. 4.7). HEK293T cells were used as negative controls that do not express 
p75NTR. An αphOx scFv was used as the comparable control to the p75NTR-specific scFvs, 
because the hapten phOx is not present in either PC12 or HEK293T cells. All the p75NTR-
specific scFvs bound to PC12 cells, while none of them showed obvious bindings to HEK 
293T cells compared to the samples stained by the αphOx scFv. 
 
4.4 No steric interference between mAb mouse anti-p75NTR (MLR2) and the 
p75NTR-specific scFvs 
In order to examine p75NTR surface knockdown by an ER-intrabodies, p75NTR needs to be 
detected through a non-overlapping epitope besides those interacted with ER-intrabodies. A 
competition ELISA was performed between mAb mouse anti-p75NTR (MLR2) and the 
p75NTR-specific scFvs (Fig. 4.8).  
Signal intensities of three p75NTR-specific scFvs were enhanced according to the 
concentration increase (Fig. 4.8 red lines). Coated p75NTR-Fc fusion proteins were 
saturated as the scFv concentration was greater than 5.0 µg/mL, since the signal intensities 
from the scFvs reached to a plateau at that concentration. In parallel, nearly constant signal 
intensities were obtained from mAb mouse anti-p75NTR (MLR2) in spite of the variations of 
scFv concentrations (Fig. 4.8 blue lines). There were practically no competitions between the 
p75NTR-specific scFvs and mAb mouse anti-p75NTR (MLR2). Therefore, the binding of mAb 
mouse anti-p75NTR (MLR2) to p75NTR was hardly interfered by the p75NTR-specific scFvs. 
The HRP conjugated secondary antibodies did not show any non-specific binding according 
to the determination of negative controls (data not shown).   
 
  Results 
51 
 
  
 
Figure 4.8 Competition ELISA between mAb mouse anti-p75NTR (MLR2) and the 
p75NTR-specific scFvs. 100 ng of mouse p75NTRex-Fc fusion protein was immobilized in BD 
plates for each well. Serial diluted p75NTR-specific scFvs were added and incubated for 1.5 hr at 
37 °C. After 3x washing with PBST, the plates were again incubated with mAb mouse anti-p75NTR 
(MLR2, 1:5,000) for 1.5 hr at 37 °C. The plates were 3x washed with PBST. Bound scFvs and mAb 
mouse anti-p75NTR (MLR2) were detected by mAb mouse anti Penta-His HRP conjugated (1:5,000) 
and pAb goat anti-mouse IgG (Fc specific) HRP conjugated (1:5,000) in corresponding plates 
respectively. 
 
4.5 Surface knockdown of p75NTR in PC12 cells by the p75NTR-specific ER-
intrabodies 
The sequences of the p75NTR-specific scFvs were subcloned into the bicistronic knockdown 
vectors (Fig. 3.2) to generate ER-intrabodies (SH325-A11-KDEL, SH325-B6-KDEL and 
SH325-G7-KDEL). P75NTR surface knockdown was firstly determined in PC12 cells. PC12 
cells were transiently transfected with the bicistronic knockdown vectors. The ER-intrabody 
αphOx-KDEL was used as the control which contained the αphOx scFv fusing to the ER 
retention signal KDEL. Four days after transfection, the p75NTR surface expression in PC12 
cells was determined in flow cytometry (Fig. 4.9). Since the ER-intrabody and reporter EGFP-
F were translated from a single transcript, it thus allowed a simple analysis of the cells 
expressing the ER-intrabodies by flow cytometry. 
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Figure 4.9 Surface knockdown of p75NTR in PC12 cells by the p75NTR-specific ER-
intrabodies. PC12 cells were transiently transfected with the p75NTR-specific ER-intrabodies and 
αphOx-KDEL. Four days after transfection, the p75NTR surface expressions were determined with 
mAb mouse anti-p75NTR (MLR2, 1:200) followed by goat anti-mouse IgG (Fcγ specific) F(ab’)
2
 
fragment APC conjugated (1:200, B, D, F, H, and J). Cells stained with secondary antibody alone were 
served as control (A, C, E, G, and I). FL1 stands for the transfected cells by showing the EGFP-F 
expression. FL4 stands for the p75NTR surface expression by illustrating the APC fluorescence. 
 
The untransfected PC12 cells showed the p75NTR expressed on their cell surfaces (Fig. 
4.9B). Cells expressing the ER-intrabodies were located in the upper and lower right 
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quadrants of the dot plots because of the EGFP-F fluorescence (Fig. 4.9D, F, H, and J). Cell 
population was expected to be shifted from the upper right quadrant to the lower right 
quadrant, if the p75NTR surface expression was downregulated by the p75NTR-specific ER-
intrabodies. There were high levels of p75NTR expressed on the surfaces of the cells 
transfected with αphOx-KDEL (Fig. 4.9D). No considerable reduction of the p75NTR surface 
expression could be detected in the SH325-A11-KDEL transfected cells (Fig. 4.9F). In the 
cells transfected with SH325-B6-KDEL, a moderate decrease of the p75NTR surface 
expression was measured (Fig. 4.9H). However, the p75NTR surface expression was 
remarkably inhibited in the SH325-G7-KDEL transfected cells, resulting in a shift of the 
transfected cell population from the FL4+ quadrant to the FL4- quadrant (Fig. 4.9J). The 
unspecific bindings were excluded by staining cells with secondary antibody alone (Fig. 4.9A, 
C, E, G, and I).  
To analyze the effects of the p75NTR-specific ER-intrabodies in more detail, an overlay 
analysis was performed between the cells expressing the p75NTR-specific ER-intrabodies 
and those expressing the control αphOx-KDEL (Fig. 4.10).  
 
 
Figure 4.10 Overlay analysis for the p75NTR surface knockdown in PC12 cells. The blue 
histograms represent the p75NTR surface expression of the PC12 cells expressing the p75NTR-
specific ER-intrabodies (SH325-A11-KDEL, SH325-B6-KDEL and SH325-G7-KDEL). The white 
histograms represent the p75NTR surface expression of the PC12 cells expressing the control αphOx-
KDEL. FL4 stands for the p75NTR surface expression by illustrating the APC signal intensity. The 
p75NTR surface knockdown ratios were indicated in percent.   
 
P75NTR knockdown ratios were calculated by comparing the mean value of APC signal 
intensity, i.e. the p75NTR surface expression level, between the cells expressing the 
p75NTR-specific ER-intrabodies and the cells expressing the control αphOx-KDEL. The 
p75NTR knockdown ratios were showed in percent. There was no decrease in the p75NTR 
surface levels in the cells expressing SH325-A11-KDEL (-6% reduction) compared to αphOx-
KDEL, whereas a slight effect was obtained from the cells expressing SH325-B6-KDEL (20% 
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reduction). The most considerable effect was acquired in the PC12 cells transfected with the 
SH325-G7-KDEL construct. Approximately 56% of surface directed p75NTR was inhibited 
from surface translocation by this ER-intrabody.  
 
4.6 Surface knockdown p75NTR in NSC19 cells by the p75NTR-specific ER-
intrabodies 
Besides PC12 cells, the effect of p75NTR-specific ER-intrabodies was also identified in 
NSC19 motor neuron cells. NSC19 was generated by fusing the mouse neuroblastoma 
N18TG2 cells with motor neuron-enriched embryonic day 12–14 mouse spinal cord cells 
(Cashman et al., 1992). It was validated to express p75NTR on cell surface. Four days after 
transfection, NSC19 cells were stained against p75NTR and subjected to flow cytometric 
analysis. An overlay analysis was carried out between the cells transfected with the p75NTR-
specific ER-intrabodies and those transfected with αphOx-KDEL ER-intrabody (Fig. 4.11).  
 
Figure 4.11 Surface knockdown of p75NTR in NSC19 cells by the p75NTR-specific ER-
intrabodies. NSC19 cells were transiently transfected with the p75NTR-specific ER-intrabodies and 
the control αphOx-KDEL. Four days after transfection, the p75NTR surface expressions were 
determined with mAb mouse anti-p75NTR (MLR2, 1:200) followed by goat anti-mouse IgG (Fcγ 
specific) F(ab’)
2
 fragment APC conjugated (1:200). Unspecific bindings were excluded by staining cells 
with secondary antibody alone (data not shown). The blue histograms represent the p75NTR surface 
expressions of the NSC19 cells expressing the p75NTR-specific ER-intrabodies (SH325-A11-KDEL, 
SH325-B6-KDEL and SH325-G7-KDEL). The white histograms represent the p75NTR surface 
expressions of the NSC19 cells expressing the control αphOx-KDEL. FL4 stands for the p75NTR 
surface expression by illustrating the APC signal intensity. The p75NTR surface knockdown ratios 
were indicated in percent.  
 
P75NTR surface knockdown ratios were calculated and the effects of the p75NTR-specific 
ER-intrabodies in NSC19 cells showed nearly the same potency on the p75NTR surface 
expression levels as in PC12 cells. The maximal knockdown ratio was obtained from SH325-
G7-KDEL (56% reduction) as it exhibited in PC12 cells. However, the SH325-A11-KDEL or 
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SH325-B6-KDEL transfected cells showed 29% or 42% reduction on the p75NTR surface 
expression respectively, which were enhanced in comparison with the results from PC12 
cells.   
 
4.7 The p75NTR-specific ER-intrabodies are expressed in different levels in 
PC12 cells 
It showed that only the ER-intrabody SH325-G7-KDEL had the obvious effect on 
downregulating the p75NTR surface expression. The ER-intrabody intracellular expressions 
were analyzed to address this question. The knockdown vectors encoding the p75NTR-
specific ER-intrabodies were transiently transfected into PC12 cells. Transfection efficiencies 
were determined in flow cytometry. Four days after transfection, 2 x 106 cells from each 
sample were lysed in 200 µL of lysis buffer. The intracellular expression of the p75NTR-
specific ER-intrabodies was evaluated by immunoblotting (Fig. 4.12A). The negative control 
resulted from the cell extracts of untransfected PC12 cells.  
 
 
Figure 4.12 Intracellular expressions of the p75NTR-specific ER-intrabodies in PC12 
cells. (A) Quantitative determination by immunoblotting. PC12 cells were transiently transfected with 
the constructs encoding the p75NTR-specific ER-intrabodies. Four days after transfection, cell extracts 
were prepared and separated by SDS-PAGE. After immunoblotting, the membrane was incubated with 
mouse anti-His5 (1:2,000) for 1 hr at RT and followed by goat anti-mouse IgG (Fab-specific) AP 
conjugated (1:5,000) for 1 hr at RT. The control resulted from the cell extracts of untransfected PC12 
cells. M stands for protein marker. Intracellular expression levels of the p75NTR-specfic ER-
intrabodies were calculated according to the scFv standard TM44 C7.3. (B) Intracellular expression 
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levels varied among the p75NTR-specific ER-intrabodies. The error bars were calculated from three 
time-independent experiments. 
 
The signal intensities were analyzed by ImageJ software. According to the calibration curve 
obtained from the scFv standard TM44 C7.3, the intracellular expressions of these p75NTR-
specific ER-intrabodies were quantitated (Fig. 4.12B). As a result, the intracellular expression 
levels of SH325-A11-KDEL (5.2 ng per 106 cells) and SH325-B6-KDEL (7.1 ng per 106 cells) 
were approximately as half as that of SH325-G7-KDEL (15.5 ng per 106 cells) in transiently 
transfected PC12 cells.  
 
4.8 P75NTR surface expression has been suppressed by the ER-intrabody 
(SH325-G7-KDEL) for more than 8 days in PC12 cells 
To analyze the kinetics of the p75NTR-specific ER-intrabody effect, a time course experiment 
of p75NTR knockdown over eight days was performed using the construct of SH325-G7-
KDEL. PC12 cells were transiently transfected with SH325-G7-KDEL and αphOx-KDEL, 
respectively. Samples were obtained at different time points and the transfected cells were 
analyzed in flow cytometry. The results were shown in Fig. 4.13. 
 
Figure 4.13 Kinetics of the p75NTR-specific ER-intrabody (SH325-G7-KDEL) effect in 
PC12 cells. PC12 cells were transiently transfected with the p75NTR-specific ER-intrabody and the 
control αphOx-KDEL. Cells were harvested at different time points. The p75NTR surface expressions 
were determined with mAb mouse anti-p75NTR (MLR2, 1:200) followed by goat anti-mouse IgG (Fcγ 
specific) F(ab’)
2
 fragment APC conjugated (1:200). The blue histograms represent the p75NTR 
surface expressions of the PC12 cells expressing SH325-G7-KDEL. The white histograms represent 
the p75NTR surface expressions of the PC12 cells expressing αphOx-KDEL. FL4 stands for the 
p75NTR surface expression by illustrating the APC signal intensity. The p75NTR surface knockdown 
ratios were indicated in percent.  
The p75NTR-specific ER-intrabody effect progressively increased from two to four days after 
transfection with SH325-G7-KDEL, and the maximal knockdown ratio (56% reduction) 
appeared at four days post-transfection. Afterwards, the surface expression level of p75NTR 
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was still suppressed in PC12 cells, although a slight increase of p75NTR surface expression 
was observed. 
  
4.9 Knockdown p75NTR by the ER-intrabody (SH325-G7-KDEL) does not 
activate the unfolded protein response (UPR) 
In order to assess the impact of the p75NTR knockdown via the ER-intrabody, it was further 
determined whether the UPR was activated during the knockdown process up to 8 days. An 
ER resident 94 kDa glucose-regulated protein (GRP94) was used as reporter protein for ER 
stress response. Its expression is upregulated due to ER stress (Bando et al., 2003). PC12 
cells were transiently transfected with SH325-G7-KDEL. Cells from different time points (2-8 
days) were sorted by BD FACSAriaTM II based on EGFP-F fluorescence, i.e. the p75NTR-
specific ER-intrabody expression. The sorting procedure was kindly performed by Dr. Lothar 
Groebe (Experimental Immunology, Helmholtz-Zentrum für Infektionsforschung (HZI), 
Germany). The possible influence of sorting efficiency on the result was extinguished since it 
was determined as about 60% for all samples. Negative and positive controls were prepared 
by treating PC12 cells with DMSO alone or 20 µg/mL of tunicamycin for 24 hr. Tunicamycin is 
known as an UPR stimulus because it inhibits N-linked glycosylation (Mahoney and Duksin, 
1979) and influences glycoprotein membrane transports (Olden et al., 1979). The expression 
levels of GRP94 were evaluated by immunoblotting (Fig. 4.14). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) served as an internal control to ensure equal protein loading and 
was detected on the same membrane.  
 
Figure 4.14 Knockdown p75NTR by the ER-intrabody (SH325-G7-KDEL) does not 
activate the UPR. The SH325-G7-KDEL transfected PC12 cells from different time points (2-8 days) 
were sorted by BD FACSAria
TM
 II based on the EGFP-F fluorescence. Cells treated with 20 µg/mL of 
tunicamycin (Tun) or solvent alone (DMSO) were used as the positive or negative control, respectively. 
Cell extracts were prepared and blotted onto a PVDF membrane. The membrane was incubated with 
rabbit anti-GRP94 (1:1,000) and rabbit anti-GAPDH (1:5,000) for 1 hr at RT. After 3x washing with 
PBST, the membrane was subsequently incubated with goat anti-rabbit IgG AP conjugated antibody 
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(1:5,000) for 1 hr at RT. GAPDH served as an internal control to ensure equal protein loading. M 
stands for protein marker.  
 
None of the GRP94 expression levels from different time point samples showed detectable 
upregulation compared to the DMSO treated negative control. In contrast, tunicamycin 
treated cells showed a considerable increase in the GRP94 expression.  
 
4.10 Suppressing p75NTR surface expression by the ER-intrabody (SH325-G7-
KDEL) impacts dendrite complexity in mouse hippocampal primary cultures  
So far, the p75NTR surface knockdown has been proved in the cell lines by the p75NTR-
specific ER-intrabody SH325-G7-KDEL. In order to evaluate the effect of this ER-intrabody in 
neurons, dissociated primary cultures of mouse hippocampal neurons were prepared using 
mice (C57 Bl/6) embryonic day E18. This work was done in collaboration with the institute for 
cellular neurobiology, TU Braunschweig (leaded by Prof. Martin Korte) and kindly helped by 
Dr. Marta Zagrebelsky and Janina Beuker.  
Primary hippocampal cultures were transfected at 7 DIV (days in vitro) using 
Lipofectamine2000 with SH325-G7-KDEL, αphOx-KDEL or fGFP, which is a vector encoding 
EGFP-F. Four days after transfection, p75NTR surface expression was detected by pAb 
rabbit anti-human p75NTR (extracellular) and anti-rabbit antibody Cy3 conjugated. Neurons 
were fixed after immunostaining to avoid permeablization. To demonstrate that neurons were 
not permeabilizated during immunocytochemistry, pAb rabbit anti-human p75NTR against 
the intracellular domain of p75NTR was used (data not shown).  
After immunostaining, transfected neurons were found either with p75NTR (p75NTR-positive) 
or without p75NTR (p75NTR-negative) surface expressions in all the samples (Fig. 4.15). 
Because the constructs of αphOx-KDEL and fGFP had no influences on p75NTR surface 
expression, the endogenously p75NTR-positive and -negative neurons were designated by 
transfected with these constructs.  
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Figure 4.15 Examples of immunofluorescence images showing p75NTR-negative 
(upper row) and p75NTR-positive (lower row) neurons after transfection with SH325-
G7-KDEL. Primary hippocampal cultures were transfected at 7 DIV (days in vitro) with SH325-G7-
KDEL. Four days after transfection, p75NTR surface expression was detected by pAb rabbit anti-
human p75NTR (extracellular, 1:1,000) and anti-rabbit antibody Cy3 conjugated (1:500). Arrows 
indicates the positions of cell somata and dendrites.   
 
Due to the expression of EGFP-F, the entire dendritic trees of transfected neurons were 
intensely labeled and could be imaged using fluorescence microscopy. Only the pyramidal 
neurons were concerned in this experiment. Morphology of the transfected neurons was 
determined by Sholl analysis (Sholl, 1953). A significant increase of dendritic complexity was 
detected in the proximal region (40 µm from the cell soma, p = 0.04) of the SH325-G7-KDEL 
transfected p75NTR-negative neurons in comparison with the p75NTR-positive neurons (Fig. 
4.16A). Furthermore, in comparison with the αphOx-KDEL or fGFP transfected p75NTR-
positive neurons, the number of dendrite crossings significantly increased in the SH325-G7-
KDEL transfected p75NTR-negative neurons (Fig. 4.16B). The significant differences were 
illustrated in the proximal region of a distance about 40-70 µm from the cell soma (p < 0.05). 
In addition, no significant alterations were found between p75NTR-positive or -negative 
neurons that were transfected with αphOx-KDEL or fGFP (Fig. 4.16C, D). 
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Figure 4.16 Sholl analysis for dendritic complexity of the p75NTR-positive and 
p75NTR-negative neurons transfected with SH325-G7-KDEL, αphOx-KDEL or fGFP. (A) 
Analysis for dendrite complexity between SH325-G7-KDEL transfected p75NTR-positive (n=13) and 
SH325-G7-KDEL transfected p75NTR-negative (n=12) neurons. (B) Analysis for dendrite complexity 
among SH325-G7-KDEL transfected p75NTR-negative (n=12), αphOx-KDEL transfected p75NTR-
positive (n=17) and fGFP transfected p75NTR-positive (n=18) neurons. (C) Analysis for dendrite 
complexity between αphOx-KDEL transfected p75NTR-positive (n=17) and αphOx-KDEL transfected 
p75NTR-negative (n=10) neurons. (D) Analysis for dendrite complexity between fGFP transfected 
p75NTR-positive (n=18) and fGFP transfected p75NTR-negative (n=13) neurons. Significant 
differences for Sholl analysis are indicated as follows: x, SH325-G7-KDEL transfected p75NTR-
negative neurons are significantly different from SH325-G7-KDEL transfected p75NTR-positive 
neurons; *, SH325-G7-KDEL transfected p75NTR-negative neurons are significantly different from 
both αphOx-KDEL transfected p75NTR-positive and fGFP transfected p75NTR-positive neurons; +, 
SH325-G7-KDEL transfected p75NTR-negative neurons are significantly different from fGFP 
transfected p75NTR-positive neurons (p <0.05). Error bars represent SEM.   
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5 Discussion 
P75 neurotrophin receptor (p75NTR) is the first neurotrophin receptor that was isolated. It 
belongs to the tumor necrosis factor receptor (TNFR) superfamily according to the death 
domain in its cytoplasmic portion. Although p75NTR has been identified to be critical in many 
aspects on the function of vertebrate neurons, its exact physiological role is not yet fully 
understood (Lu et al., 2005; Nykjaer et al., 2005; Yamashita et al., 2005). P75NTR normally 
has to collaborate with many different protein partners because of the lack of intrinsic kinase 
signaling in its intracellular region and the functions of p75NTR strongly depending on the 
molecular and cellular context (Hempstead, 2002). It mediates neurite outgrowth, cell 
apoptosis as well as cell survival (Dechant and Barde, 1997; Yoon et al., 1998; Mi et al., 
2004; Nykjaer et al., 2004; Sole et al., 2004). Recent works also indicate that p75NTR 
regulates neurogenesis and long-term depression (LTD) in mouse hippocampus and further 
implicate that p75NTR plays an essential role in learning and memory formation in brain 
(Rosch et al., 2005; Woo et al., 2005; Catts et al., 2008). 
So far, most functional studies of p75NTR have been employing gene knockout p75NTR-/- 
mice. However, gene-targeted knockout is a time-consuming work on one hand, and 
alternative splicing products, on the other hand, have been reported in both p75NTRexonIII and 
p75NTRexonIV knockout phenotypes (von Schack et al., 2001; Paul et al., 2004). These 
alternative splicing products are suggested to be proapoptotic fragments since both of them 
contain the intact intracellular domain of p75NTR. This postulation was proved by the recent 
work. Overexpression of the p75NTR intracellular domain in mice led to increased neuronal 
death in both the central and peripheral nervous system (Majdan et al., 1997). In addition, 
p75NTR has been shown to undergo α- and then γ-secretase intramembrane proteolytic 
cleavage releasing its intracellular C-terminal fragment (Jung et al., 2003; Kanning et al., 
2003). The translocation of the p75NTR intracellular fragment derived from γ-secretase 
processing to the nucleus (Kanning et al., 2003) implies that it may act as an important role in 
nuclear signaling.  
Besides gene-target knockout, several knockdown techniques have been applied to inhibit 
specific protein functions, such as siRNAs, RNA apatmers and ER-intrabodies (Mocellin and 
Provenzano, 2004; Boldicke, 2007; Yan and Levy, 2009). Among these approaches, ER-
intrabodies trap specific targets within the ER by constructing an ER retention signal at C-
terminal. In contrast to the gene-targeted knockout or RNAi technology that silence gene 
expression, ER-intrabodies provide the possibility to neutralize the functions of specific 
secretory proteins at the post-translational level and thus avoid the probable generation of 
abnormal splicing products. Besides high affinity and specificity, ER-intrabodies are very 
stably expressed in mammalian cells compared to siRNAs (Fish and Kruithof, 2004) or 
aptamers (Famulok et al., 2000). Moreover, siRNAs have been identified to activate an 
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interferon-mediated activation of the JAK/STAT (Janus kinase/signal transducer and activator 
of transcription) pathway, resulting in unknown effects in target cells (Sledz et al., 2003). 
Whereas intrabody may prove be less immunogenic than other therapeutics and thereby 
suggests it can be potentially useful in the therapeutical applications, especially in 
neurodegenerative diseases (Kontermann, 2004; Miller and Messer, 2005). To date, ER-
intrabody knockdown technology is becoming one of potent tools to downregulate target 
protein function. 
ScFvs become the most use in intrabody applications in the past decade. Because of the 
small size, scFvs are easily expressed and assembled as functional molecules. Many 
techniques have been developed for scFv screening, and phage display panning has 
become the most robust, versatile and widespread method over the past 10 years (Hust et al., 
2007b). Based on antibody libraries, recombinant scFvs specific to nearly any target antigen 
can be isolated in vitro at high throughput in a relative short period. In this work, antibody 
fragments in scFv formats were isolated by phage display against the recombinant antigen of 
p75NTRex-Fc. The antigen p75NTRex-Fc was produced by fusing the extracellular domain 
of mouse p75NTR with the human IgG1 Fc domain to improve secretory expression in 
mammalian cells and facilitate purification by protein A. The purity and size of p75NTRex-Fc 
were demonstrated by immunoblotting. As a consequence of the glycosylations of p75NTR 
(Gong et al., 2008) and IgG1 Fc domain (Lund et al., 1996; Jefferis et al., 1998), purified 
p75NTRex-Fc fusion protein migrated to ca. 100 kDa on the membrane. 
Three scFvs, SH325-A11, SH325-B6 and SH325-G7, against the extracellular domain of 
mouse p75NTR were selected from the naïve human antibody gene libraries HAL4 (Kappa) 
and HAL7 (Lambda) after three panning rounds (Hust et al., 2007b; Kirsch et al., 2008; 
Schütte et al., 2009). The p75NTR-specific scFvs were selected against the recombinant 
p75NTRex-Fc directly immobilized onto the plastic surface in immunostripes in panning 
procedure. The p75NTR-specific scFvs were produced by periplasmic expression in E. coli 
and purified using IMAC.  
It was important that the candidate scFvs were not cross-reactive with other neuronal 
receptors, such as TrkA and TrkB, which were related but probably antagonistically functional 
to p75NTR. In siRNA knockdown technique, the specificity of siRNA is continually argued 
due to its off-target effects (Couzin, 2004). All selected scFvs showed high specificities to 
p75NTR, but not other neuronal proteins used as controls in the antigen binding ELISA 
determination.  
The affinities were determined for these p75NTR-specific scFvs by SPR. All the p75NTR-
specific scFvs have the affinities in the range of naomolar, which are expected for isolated 
antibody fragments from naïve antibody gene library by phage display (Griffiths et al., 1994).  
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Since the direct coating may lead protein into a partial denaturation, it is necessary to identify 
the native conformational p75NTR can be recognized by the scFvs selected against the 
directly immobilized recombinant p75NTR. In flow cytometric analysis, all the p75NTR-
specific scFvs bound to PC12 cells that express p75NTR, whereas they did not bind to 
HEK293T cells that are negative for p75NTR.  It is well known that the post-translational 
modifications are completed within the ER before they are transported to Golgi complex and 
secreted to the cell surface. Hence, the recognition of native p75NTR on the PC12 cell 
surface strongly indicates that the p75NTR-specific scFvs are also capable to associate with 
p75NTR in the ER.  
In order to knockdown p75NTR, the p75NTR-specific scFvs were engineered with the C-
terminal ER retention motif KDEL to generate the ER-intrabodies, SH325-A11-KDEL, SH325-
B6-KDEL and SH325-G7-KDEL. Additionally, the His6-tag sequence was inserted between 
the scFv and the KDEL allowing detection. The conformations of scFvs are supposed not to 
be changed with these motifs, since the His6-tag and KDEL sequence have little effect on the 
native protein structure, and the scFv stability may increase in the presence of KDEL 
(Schouten et al., 1996; Carson et al., 2007). In order to transfer the ER-intrabodies into 
mammalian cells, a novel bicistronic knockdown vector was constructed (Fig 3.1). The first 
cistron ER-intrabody was mediated by a CMV promoter, while the EGFP-F was directed as 
the second cistron by a mutant EMCV IRES element in cap-independent mechanism. EGFP-
F is a farnesylated form of EGFP that remains bound to the plasma membrane in both living 
and fixed cells. Because the ER-intrabody and EGFP-F are simultaneously translated from a 
single transcript, the intrabody-expressing cells can be easily distinguished in flow cytometry 
and fluorescence microscopy.  
The effect of the p75NTR-specific ER-intrabodies on the p75NTR surface expression was 
firstly demonstrated in PC12 cells. Four days after transfection with the ER-intrabody 
constructs, the p75NTR surface expressions were determined by a detection antibody, mAb 
mouse anti-p75NTR (MLR2). As shown in the competition ELISA, there are no steric 
interference between mAb mouse anti-p75NTR (MLR2) and the p75NTR-specific scFvs. 
Hence, the downregulations of p75NTR surface expression levels can only be caused by the 
effect of the p75NTR-specific ER-intrabodies. In flow cytometric analysis, the p75NTR 
surface expression was only dramatically downregulated by SH325-G7-KDEL, which has the 
lowest affinity among the p75NTR-specific ER-intrabodies. This phenomenon was also found 
in p75NTR-expressing NSC19 cells. Although SH325-A11-KDEL and SH325-B6-KDEL 
showed enhanced p75NTR surface knockdown ratios in NSC19 cells compared to PC12 
cells, the maximal knockdown ratio was obtained from SH325-G7-KDEL. Considering that 
SH325-G7-KDEL expressed much more strongly than SH325-A11-KDEL and SH325-B6-
KDEL in transiently transfected PC12 cells, it seems that the intracellular expression amount 
of ER-intrabody is one of the pivotal factors that impact the effect on target protein 
knockdown. The enhanced effects of SH325-A11-KDEL and SH325-B6-KDEL in NSC19 
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cells might arise from the improvement of the ER-intrabody intracellular expressions. 
However, the knockdown ratio might not be strengthened when certain expression level was 
reached for an ER-intrabody, as shown by SH325-G7-KDEL. Improvement of the ER-
intrabody affinity or avidity becomes a promising way to increase the knockdown ratio in that 
situation. In SH325-G7-KDEL transfected PC12 cells, the maximal p75NTR knockdown ratio 
(56% reduction) was calculated in comparison with the αphOx-KDEL transfected cells. It has 
illustrated that there were cells detected as p75NTR negative in all samples independent on 
the knockdown construct transfer (Fig. 4.9B, D, F, H, and J). This is probably the reason that 
the knockdown ratio could not be calculated as high as the former works in which the cells 
were engineered for target overexpression. 
A time course experiment was performed using the construct of SH325-G7-KDEL to analyze 
the kinetics of the p75NTR-specific ER-intrabody effect on regulating the p75NTR surface 
expression. Previous researches have suggested that ER-intrabody strategy led to a time-
dependent downregulation of target protein expression. After transfection with specific ER-
intrabodies, the surface expression of ErbB-2 (Curiel et al., 2000) and VCAM-1 (Strebe et al., 
2009) had been progressively suppressed from 48 to 96 hr. Consistent with these results, the 
maximal efficiency of p75NTR knockdown by the ER-intrabody SH325-G7-KDEL appeared 
four days after transfection, and the effect persisted more than eight days post-transfection, 
although the p75NTR surface expression was increased slightly. In contrast to siRNA which 
normally maintains its effect on target knockdown for 3-5 days (Zou et al., 2007), the long 
turnover kinetics of the ER-intrabody effect facilitates the investigation of the role of p75NTR 
in nerve system over a long period. 
It is known that overexpression of heterologous proteins might saturate the cell’s capacity for 
the protein folding, causing ER stress and resulting in the UPR initiation (Raden et al., 2005). 
If the proper protein folding is not restored, the activation of UPR will signal an apoptotic 
response (Meusser et al., 2005; Schroder, 2008). Moreover, the prolonged ER stress could 
lead to neurons death and arise the pathogenesis of neurodegenerative disorders (Malhotra 
and Kaufman, 2007). Hence, it is important to determine whether the UPR is activated during 
the knockdown process by the p75NTR-specific ER-intrabody. The ER-resident molecular 
chaperone GRP94 is one of the ER stress indicators since it has been demonstrated that the 
expression of GRP94 is upregulated by the UPR initiation (Bando et al., 2003). GRP94 plays 
a pivotal role in the UPR by slowing down the protein folding process and marking unfolded 
proteins (Schroder, 2008). The expression levels of GRP94 were evaluated by 
immunoblotting in order to indicate the UPR in the PC12 cells expressing the ER-intrabody 
SH325-G7-KDEL. In comparison with DMSO treated PC12 cells, the expression levels of 
GRP94 were not increased in transfected PC12 cells during the time course knockdown 
experiment over eight days. However, tunicamycin, an UPR stimulus, considerably provoked 
the GRP94 expression in PC12 cells. Thus, the UPR was not activated by the ER-intrabody 
SH325-G7-KDEL transfection and expression. Furthermore, it implicates that the complexes 
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of ER-intrabodies and p75NTR may not accumulated within the ER, but be degraded via ER-
associated degradation (ERAD) pathway (Meusser et al., 2005). 
Finally, the ER-intrabody SH325-G7-KDEL was applied to mouse hippocampal primary 
cultures prepared from mice (C57 Bl/6) embryonic day 18. Although p75NTR only abundantly 
expresses during development period, it is known to be present in hippocampal neurons of 
adult brains of mouse, rat, and human (Koh et al., 1989; Kerwin et al., 1993; Catts et al., 
2008). These findings imply that p75NTR has a critical role in modulating many aspects of 
hippocampal functions and behaviors. Since p75NTR is only present in about half of the 
pyramidal neurons of the CA1-CA4 subfields of hippocampus (Hu et al., 2002), the 
endogenously p75NTR-positive and -negative neurons were indicated with αphOx-KDEL or 
fGFP transfection. Nonetheless, the p75NTR-positive neurons were also found in SH325-G7-
KDEL transfected neurons, in which p75NTR surface expressions were supposed to be 
completely eliminated. It might arise from the inconstant expression of p75NTR in the 
p75NTR-expressing pyramidal neurons (Zagrebelsky et al., 2005). The expression level of 
the ER-intrabody SH325-G7-KDEL may be efficient for some neurons but inefficient for the 
others to abolish the p75NTR surface expression completely.  
In order to study the effect of the ER-intrabody in neurons, dendritic morphologies of 
transfected neurons were analyzed by fluorescence microscopy according to the intense 
labeling by EGFP-F. It is revealed that the dendritic complexity was significantly increased in 
the proximal region of the SH325-G7-KDEL transfected p75NTR-negative neurons, 
compared to the p75NTR-positive neurons (Fig. 4.16A, B). However, the endogenously 
p75NTR-negative neurons cannot be distinguished from the p75NTR-negative neurons due 
to the ER-intrabody effect in the SH325-G7-KDEL transfected neurons. Therefore, further 
analyses were performed in order to determine if the increase in the dendritic complexity was 
caused by the p75NTR surface knockdown. There were no significant changes in dendritic 
morphology observed between the endogenously p75NTR-positive and -negative neurons 
that were indicated with αphOx-KDEL or fGFP transfection (Fig. 4.16C, D). Taking into 
account that dendritic growth and branching are affected by many other intrinsic and extrinsic 
factors (McAllister et al., 1997; Threadgill et al., 1997; Hakeda-Suzuki et al., 2002; Luo, 2002; 
Wang et al., 2002; Gao and Bogert, 2003), it implies that the endogenously p75NTR-negative 
neurons may be negatively modulated in their dendritic complexities in some mechanisms 
other than p75NTR, and may behavior different from the endogenously p75NTR-positive 
neurons. Hence, the increase in the dendritic complexity is owing to the inhibition of p75NTR 
surface translocation by the ER-intrabody SH325-G7-KDEL. It likely indicates that p75NTR 
might be one of the factors that suppressed dendritic branching in mouse hippocampal 
neurons. This result was highly consistent with the previous finding that p75NTR negatively 
modulated dendrite complexity and spine density in hippocampal neurons (Zagrebelsky et al., 
2005).  
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In summary, three p75NTR-specific scFvs with nanomolar affinities were selected by phage 
display. The p75NTR-specific ER-intrabodies were generated by adding the C-terminal ER 
retention signal KDEL, and the construct SH325-G7-KDEL showed a remarkable effect on 
downregulating the p75NTR surface expression in PC12 and NSC19 cells. The effect of 
SH325-G7-KDEL maintained more than eight days on suppressing the surface translocation 
of p75NTR in PC12 cells, without obviously activating the UPR. It was also demonstrated 
that the intracellular expression level of ER-intrabody intensely influences the effect of ER-
intrabody on the p75NTR surface knockdown. Finally, the p75NTR surface knockdown was 
determined in the mouse hippocampal primary cultures by SH325-G7-KDEL. It implicates 
that p75NTR may act essentially on modulating the dendritic morphology of hippocampal 
neurons, since the dendritic complexity was significantly increased when the p75NTR surface 
expression was reduced by the ER-intrabody.  
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6 Outlook 
As shown in this study, the low intracellular expression level of ER-intrabody resulted in the 
inefficient target knockdown, while SH325-G7-KDEL with high expression efficiency could 
intensely downregulate the p75NTR surface expression in mammalian cells. However, the 
expression level of ER-intrabody cannot be unlimitedly enhanced because overexpressions 
of heterologous proteins may initiate the UPR in the cells and lead to cell apoptosis. Thus, 
increasing the binding affinity and avidity of ER-intrabody became necessary to improve the 
target surface knockdown. Many efforts have been investigated for antibody engineering to 
obtain higher affinity and avidity, increased half-life and stability. The affinities of antibody 
fragments could be augmented through targeted mutagenesis of CDRs or error prone PCR 
(Osbourn et al., 1996; Colby et al., 2004). In order to increase the avidity, bivalent antibody 
fragments can be produced by engineering an Fc domain to the C-terminal of scFv or 
constructing scFvs as diabodies (Holliger et al., 1993; Demarest and Glaser, 2008). 
Furthermore, the in vivo stability of an antibody fragment will be dramatically improved as a 
result of the change of a scFv fragment into a Fab format (Quintero-Hernandez et al., 2007).  
In addition, multiple-target knockdown will be approached in the future from a single 
transcript according to the cap-independent translation mechanism directed by a mutant 
IRES (Li et al., 2007). This IRES was genetically modified without obviously losing the 
translation efficiency in order that a new ER-intrabody could be inserted with one single 
cloning step.  
The dendritic morphology of mouse hippocampal primary neurons was shown significantly 
modulated by the p75NTR-specific ER-intrabody SH325-G7-KDEL. However, the distinct 
apical and basal dendrites are often failed to be formed in the pyramidal neurons from 
dissociated cultures (Dotti et al., 1988; Collin et al., 1997). It seems that the dissociated 
primary culture is not the entirely analogue of hippocampus. Therefore, hippocampal 
organotypic slices need to be applied to investigate the substantial roles of p75NTR.  
Although several approaches had been developed to silence the particular target 
expressions, ER-intrabody knockdown technology became one promising method to 
neutralize and study the functions of specific secretory proteins. The less immunogenic 
response might provide this technology to be more potential in the therapeutically 
applications, for example neurodegenerative diseases (Taylor et al., 2002). In the past 
decades, more and more intrabodies had been generated to use in a wide range of 
applications, including HIV infection, tumor therapy, tissue transplantation, and treatments of 
neurological disorders (Kontermann, 2004; Miller and Messer, 2005; Boldicke, 2007). 
Moreover, proteome binder project has been started to generate recombinant antibodies 
against all human proteins, including variant forms and modifications. Thus ER-intrabodies 
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can be easily generated based on these present recombinant antibodies to investigate the 
functions of specific human surface proteins, including the uncharacterized, by inhibiting 
them from surface translocations.   
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